Antibody-drug conjugates

Abstract

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

Description

PC040972A ANTIBODY-DRUG CONJUGATES

[0001] Incorporated by reference herein for all purposes is the content of U.S. Provisional Patent Application No.63 / 620,599 (filed January 12, 2024). FIELD

[0002] The present disclosure relates to methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody- drug conjugate (ADC); and / or methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. Compositions, uses, and kits related thereto are also provided. BACKGROUND

[0003] Antibody-drug conjugates represent powerful therapeutic modalities due to their ability to selectively target highly toxic payloads to cells bearing target antigens. However, ADCs can also cause unwanted side effects such as off-target cytotoxicity. Various strategies have been examined to improve the safety of ADCs. See, e.g., Aoyama, M. et al. (2022) Pharm Res.39(1):89-103; Conilh, L. et al. (2023) J. Hematol Oncol.16 doi: 10.1186 / s13045-022-01397-y; and US PG Pub No. US2020 / 0376135.

[0004] As such, a need remains for reducing the likelihood and / or severity of adverse events associated with ADC-based treatments, as well as for increasing dosing amount and / or frequency of ADCs.

[0005] All references cited herein, including patent applications, patent publications, and UniProtKB / Swiss-Prot Accession numbers are herein incorporated by reference in their entirety, as if each individual reference were specifically and individually indicated to be incorporated by reference. SUMMARY

[0006] In some aspects, provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody- drug conjugate (ADC), comprising administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function, and wherein the administration of the ADC results in decreased likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in the individual, as compared to likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0007] In some embodiments, the administration results in decreased likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in the individual, as compared to likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration results in decreased likelihood and / or severity of neutropenia and / or neutrophil count decrease in the individual, as compared to likelihood and / or severity of neutropenia and / or neutrophil count decrease in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the neutropenia does not comprise febrile neutropenia. In some embodiments, the peripheral neuropathy, anemia, and / or neutropenia comprises grade 3 or grade 4 peripheral neuropathy, anemia, and / or neutropenia. In some embodiments, the administration results in a reduction in the likelihood of peripheral neuropathy in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%, as compared to the likelihood of peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration results in a reduction in the likelihood of grade 3 or grade 4 peripheral neuropathy in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%, as compared to the likelihood of grade 3 or grade 4 peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration does not result in grade 3 or grade 4 peripheral neuropathy in the individual. In some embodiments, the administration results in a reduction in the likelihood of anemia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, as compared to the likelihood of anemia in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration results in a reduction in the likelihood of grade 3 or grade 4 anemia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as compared to the likelihood of grade 3 or grade 4 anemia in an individual administered an ADC comprising a human Fc region with wild- type effector function. In some embodiments, the administration results in a reduction in the likelihood of neutropenia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, as compared to the likelihood of neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration results in a reduction in the likelihood of grade 3 or grade 4 neutropenia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as compared to the likelihood of grade 3 or grade 4 neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0008] In some aspects, provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual, comprising administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function, and wherein the ADC is administered to the individual at an increased amount and / or at a higher frequency, as compared to amount and / or frequency of dosing in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0009] In some embodiments, the ADC is administered to the individual at an increased amount, as compared to an amount of an ADC comprising a human Fc region with wild-type effector function administered to the individual. In some embodiments, the ADC is administered to the individual at an increased frequency, as compared to a frequency of administration of an ADC comprising a human Fc region with wild-type effector function to the individual. In some embodiments, the ADC is administered to the individual at an increased amount as compared to a reference amount, and wherein the administration of the ADC at the increased amount does not increase likelihood and / or severity of one or more adverse events in the individual, as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference amount. In some embodiments, the ADC is administered to the individual at an increased frequency as compared to a reference frequency, and wherein the administration of the ADC at the increased frequency does not increase likelihood and / or severity of one or more adverse events in the individual, as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference frequency. In some embodiments, the one or more adverse events comprise peripheral neuropathy, anemia, and / or neutropenia. In some embodiments, the one or more adverse events comprise grade 3 or grade 4 peripheral neuropathy, anemia, and / or neutropenia.

[0010] In some embodiments according to any of the embodiments described herein, the human Fc region has reduced or eliminated binding to one or more human Fc receptor(s), as compared to binding of a human Fc region with wild-type effector function to the one or more human Fc receptor(s). In some embodiments, the one or more human Fc receptor(s) are human FcγRI, FcγRII, and / or FcγRIII Fc receptors. In some embodiments, the human Fc region has reduced or eliminated binding to complement C1q, as compared to binding of a human Fc region with wild-type effector function to complement C1q. In some embodiments, the human Fc region comprises one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human Fc region. In some embodiments, the human Fc region is a human IgG1 Fc region comprising one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human IgG1 Fc region. In some embodiments, the human Fc region is a human IgG1 Fcregion comprising an amino acid substitution at one or more of position(s) L234, L235, G236, and / or G237, numbering according to EU index. In some embodiments, the human Fc region is a human IgG1 Fc region comprising amino acid substitution(s) at position(s) L234 and / or L235, numbering according to EU index. In some embodiments, the human Fc region is a human IgG1 Fc region comprising L234A and L235A substitutions, numbering according to EU index. In some embodiments, the human Fc region is a human IgG2 Fc region comprising one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human IgG2 Fc region. In some embodiments, the human Fc region is a human IgG4 Fc region.

[0011] In some embodiments according to any of the embodiments described herein, the individual has or has been diagnosed with cancer. In some embodiments, the individual is being treated for cancer. In some embodiments, the cancer is melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, or cervical cancer. In some embodiments, the antibody binds to human PD-L1. In some embodiments, the antibody comprises heavy chain CDR sequences of SEQ ID NOs: 13-15 and light chain CDR sequences of SEQ ID NOs: 16-18. In some embodiments, the antibody comprises a heavy chain variable region sequence of SEQ ID NO: 11 and a light chain variable region sequence of SEQ ID NO: 12. In some embodiments, the antibody comprises a light chain of SEQ ID NO: 9 and a heavy chain of SEQ ID NO: 10. In some embodiments, the antibody binds to human B7-H4, CD19, CD30, CD33, CD70, CD228, ITGB6 (integrin beta 6), Nectin-4, TF (tissue factor), Her2, STn, ALPP, or LIV-1.

[0012] In some embodiments according to any of the embodiments described herein, the drug moiety is a cytotoxic agent, growth inhibitory agent, or chemotherapy. In some embodiments, the cytotoxic agent is a tubulin disrupting agent or tubulin / microtubule inhibitor. In some embodiments, the cytotoxic agent is an auristatin, anthracycline, camptothecin, taxane or taxane analog, vinca alkyloid, baccatin derivative, nocodazole, colchicine, colcimid, estramustine, cryptophysin, cemadotin, maytansinoid, combretastatin, discodermoide, eleuthrobin, or tubulysin. In some embodiments, the drug moiety is monomethyl auristatin E (MMAE). In some embodiments, the antibody is conjugated to MMAE via a linker forming an antibody-drug conjugate having the structure:wherein Ab represents the antibody and p ranges from 2 to 10. In some embodiments, p is 4. In some embodiments, p is 8. In some embodiments, the cytotoxic agent is camptothecin. In some embodiments, the antibody is conjugated to camptothecin via a linker forming an antibody-drug conjugate having the structure:wherein Ab represents the antibody and p ranges from 2 to 10. In some embodiments, p is 4. In some embodiments, p is 8.

[0013] In some embodiments according to any of the embodiments described herein, the linker is an enzyme-cleavable linker.

[0014] It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the invention will become apparent to one of skill in the art. These and other embodiments of the invention are further described by the detailed description that follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG.1 shows the incidence of adverse events of special interest observed in phase 1 testing of an anti-PD-L1 antibody-drug conjugate (ADC) having a human IgG1 Fc region comprising L234A / L235A mutations, as compared to two other antibody-drug conjugates that include the same drug payload (vedotin) but comprise antibodies (not targeted to PD-L1) with a wild-type human IgG1 Fc region. ^ includes neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia;$22 / 54 have received more than 4 courses. DETAILED DESCRIPTION I. Definitions

[0016] Before describing the invention in detail, it is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0017] As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a molecule” optionally includes a combination of two or more such molecules, and the like.

[0018] The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.

[0019] It is understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

[0020] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei- Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure. For purposes of the present disclosure, the following terms are defined.

[0021] The term "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0022] The terms “about” and “approximately” as used herein shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Any reference to “about X” specifically indicates at least the values X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Thus, “about X” is intended to teach and provide written description support for a claim limitation of, e.g ., “0.98X.” The terms “about” and “approximately,” particularly in reference to a given quantity, encompass and describe the given quantity itself.

[0023] Alternatively, in biological systems, the terms “about” and “approximately” may mean values that are within an order of magnitude, preferably within 5-fold, and more preferably within 2- fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.

[0024] When “about” is applied to the beginning of a numerical range, it applies to both ends of the range. Thus, “from about 5 to 20%” is equivalent to “from about 5% to about 20% ” When “about” isapplied to the first value of a set of values, it applies to all values in that set. Thus, “about 7, 9, or 11 mg / kg” is equivalent to “about 7, about 9, or about 11 mg / kg.”

[0025] "Administering" or “administration” refer to the physical introduction of a therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration include oral, intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion ( e.g intravenous infusion). The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation. A therapeutic agent can be administered via a non-parenteral route, or orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administration can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0026] A "cancer" refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. A "cancer" or "cancer tissue" can include a tumor.

[0027] The term “metastasis” is an art known term that refers to the spread of cancer cells from the place where they first formed (the primary site) to one or more other sites in a subject (one or more secondary sites). In metastasis, cancer cells break away from the original (primary) tumor, travel through the blood or lymph system, and form a new tumor (a metastatic tumor) in other organs or tissues of the body. The new, metastatic tumor includes the same or similar cancer cells as the primary tumor. At the secondary site, the tumor cell may proliferate and begin the growth or colonization of a secondary tumor at this distant site.

[0028] The term “antibody-drug conjugate” refers to an antibody or antigen-binding fragment thereof conjugated to a therapeutic agent (i.e., a drug or cytotoxic molecule) optionally via a linker.

[0029] As used herein, an “antibody” can include monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules), as well as antibody fragments (e.g., Fab, F(ab')2, and Fv). The term “immunoglobulin” (Ig) is used interchangeably with “antibody” herein. An “antibody” or “immunoglobulin” can refer to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) low molecular weight chains and one pair of heavy (H) chains, all four inter-connected by disulfide bonds. The structure of immunoglobulins has been well characterized. See for instance Fundamental Immunology Ch.7 (Paul, W., ed., 2nd ed. Raven Press, N .Y. (1989)). Briefly, eachheavy chain typically is comprised of a heavy chain variable region (abbreviated herein as VH or VH) and a heavy chain constant region (CH or CH). The heavy chain constant region typically is comprised of three domains, CH1, CH2, and CH3. The heavy chains are generally inter-connected via disulfide bonds in the so-called “hinge region.” Each light chain typically is comprised of a light chain variable region (abbreviated herein as VL or VL) and a light chain constant region (CL or CL). The light chain constant region typically is comprised of one domain, CL. The CL can be of κ (kappa) or λ (lambda) isotype. The terms “constant domain” and “constant region” are used interchangeably herein. An immunoglobulin can derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG, and IgM. IgG subclasses are also well known to those in the art and include but are not limited to human IgG1, IgG2, IgG3 and IgG4. "Isotype" refers to the antibody class or subclass (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes.

[0030] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable regions of the heavy chain and light chain (VH and VL, respectively) of a native antibody may be further subdivided into regions of hypervariability (or hypervariable regions, which may be hypervariable in sequence and / or form of structurally defined loops), also termed complementarity-determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). The terms “complementarity determining regions” and “CDRs,” synonymous with “hypervariable regions” or “HVRs” are known in the art to refer to non-contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and / or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” and “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4). Within each VH and VL, three CDRs and four FRs are typically arranged from amino- terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (See also Chothia and Lesk J. Mot. Biol., 195, 901-917 (1987)).

[0031] Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')2fragment that has two antigen-combining sites and is still capable of cross-linking antigen. The Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.

[0032] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Although the boundaries ofthe Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. In some embodiments, an Fc region includes antibody second constant (CH2) and third constant (CH3) domains of the heavy chain. Suitable native-sequence Fc regions for use in the antibodies of the present disclosure include human IgG1, IgG2, IgG3 and IgG4. A single amino acid substitution (S228P according to Kabat numbering; designated IgG4Pro) may be introduced to abolish the heterogeneity observed in recombinant IgG4 antibody. See Angal, S. et al. (1993) Mol Immunol 30, 105–108. The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences of Immunological Interest.5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The “EU numbering system” or “EU index” is generally used when referring to a residue in an immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al., supra). The “EU index as in Kabat” refers to the residue numbering of the human IgG1 EU antibody.

[0033] The term “antibody” (Ab) in the context of the present invention refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of either thereof, which has the ability to specifically bind to an antigen under typical physiological conditions with a half-life of significant periods of time, such as at least about 30 min, at least about 45 min, at least about one hour (h), at least about two hours, at least about four hours, at least about eight hours, at least about 12 hours (h), about 24 hours or more, about 48 hours or more, about three, four, five, six, seven or more days, etc., or any other relevant functionally-defined period (such as a time sufficient to induce, promote, enhance, and / or modulate a physiological response associated with antibody binding to the antigen and / or time sufficient for the antibody to recruit an effector activity). The variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen. The constant regions of the antibodies (Abs) may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system such as C1q, the first component in the classical pathway of complement activation. An antibody may also be a bispecific antibody, diabody, multispecific antibody or similar molecule.

[0034] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules that are recombinantly produced with a single primary amino acid sequence. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Accordingly, the term "human monoclonal antibody" refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. The human monoclonal antibodies may be generated by a hybridoma which includes a B cell obtained from a transgenic or transchromosomal non-human animal, such as a transgenic mouse,having a genome comprising a human heavy chain transgene and a light chain transgene, fused to an immortalized cell.

[0035] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds specifically to PD-L1 is substantially free of antibodies that bind specifically to antigens other than PD-L1). An isolated antibody that binds specifically to PD-L1 can, however, have cross-reactivity to other antigens, such as PD-L1 molecules from different species. Moreover, an isolated antibody can be substantially free of other cellular material and / or chemicals. In one embodiment, an isolated antibody includes an antibody conjugate attached to another agent (e.g., small molecule drug).

[0036] An "antigen-binding portion" or antigen-binding fragment” of an antibody refers to one or more fragments of an antibody that retain the ability to bind specifically to the antigen bound by the whole antibody. Examples of antibody fragments (e.g., antigen-binding fragment) include but are not limited to Fv, Fab, Fab', Fab’-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab’)2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

[0037] As used herein, the terms “binding”, "binds" or "specifically binds" in the context of the binding of an antibody to a pre-determined antigen typically is a binding with an affinity corresponding to a KD of about 10-6M or less, e.g.10-7M or less, such as about 10-8M or less, such as about 10-9M or less, about 10-10M or less, or about 10-11M or even less when determined by for instance BioLayer Interferometry (BLI) technology in a Octet HTX instrument using the antibody as the ligand and the antigen as the analyte, and wherein the antibody binds to the predetermined antigen with an affinity corresponding to a KD that is at least ten-fold lower, such as at least 100-fold lower, for instance at least 1,000-fold lower, such as at least 10,000-fold lower, for instance at least 100,000- fold lower than its KDof binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely related antigen. The amount with which the KD of binding is lower is dependent on the KD of the antibody, so that when the KD of the antibody is very low, then the amount with which the KDof binding to the antigen is lower than the KDof binding to a non-specific antigen may be at least 10,000-fold (that is, the antibody is highly specific).

[0038] The term "KD" (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. Affinity, as used herein, and KDare inversely related, that is that higher affinity is intended to refer to lower KD, and lower affinity is intended to refer to higher KD.

[0039] The term "ADC" refers to an antibody-drug conjugate, which is coupled to a drug moiety (e.g., MMAE or MMAF) as described in the present application.

[0040] The abbreviations "vc" and "val-cit" refer to the dipeptide linker valine-citrulline.

[0041] The abbreviation VKG refers to the tripeptide linker valine-lysine-glycine.

[0042] The abbreviation "MC" refers to the stretcher maleimidocaproyl:

[0043] The abbreviation "MP" refers to the stretcher maleimidopropionyl:

[0044] “PEG Unit” as used herein is an organic moiety comprised of repeating ethylene-oxy subunits (PEGs or PEG subunits) and may be polydisperse, monodisperse or discrete (i.e., having discrete number of ethylene-oxy subunits). Polydisperse PEGs are a heterogeneous mixture of sizes and molecular weights whereas monodisperse PEGs are typically purified from heterogeneous mixtures and are therefore provide a single chain length and molecular weight. Preferred PEG Units comprises discrete PEGs, compounds that are synthesized in step-wise fashion and not via a polymerization process. Discrete PEGs provide a single molecule with defined and specified chain length.

[0045] The PEG Unit provided herein comprises one or multiple polyethylene glycol chains, each comprised of one or more ethyleneoxy subunits, covalently attached to each other. The polyethylene glycol chains can be linked together, for example, in a linear, branched or star shaped configuration. Typically, at least one of the polyethylene glycol chains prior to incorporation into a camptothecin conjugate is derivatized at one end with an alkyl moiety substituted with an electrophilic group for covalent attachment to the carbamate nitrogen of a methylene carbamate unit (i.e., represents an instance of R). Typically, the terminal ethyleneoxy subunit in each polyethylene glycol chains not involved in covalent attachment to the remainder of the Linker Unit is modified with a PEG Capping Unit, typically an optionally substituted alkyl such as –CH3, CH2CH3 or CH2CH2CO2H. A preferred PEG Unit has a single polyethylene glycol chain with 2 to 24 –CH2CH2O- subunits covalently attached in series and terminated at one end with a PEG Capping Unit.

[0046] The term "antibody-dependent cellular cytotoxicity", or ADCC, is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with immune cells possessing lytic activity (also referred to as effector cells). Such effector cells include natural killer cells, monocytes / macrophages and neutrophils. The effector cells attach to an Fc effector domain(s) of Ig bound to target cells via their antigen-combining sites. Death of the antibody-coated target cell occurs as a result of effector cell activity.

[0047] The term "antibody-dependent cellular phagocytosis", or ADCP, refers to the process by which antibody-coated cells are internalized, either in whole or in part, by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells) that bind to an Fc effector domain(s) of Ig.

[0048] The term "complement-dependent cytotoxicity", or CDC, refers to a mechanism for inducing cell death in which an Fc effector domain(s) of a target-bound antibody activates a series of enzymatic reactions culminating in the formation of holes in the target cell membrane. Typically, antigen-antibody complexes such as those on antibody- coated target cells bind and activate complement component C1q which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes.

[0049] "Treatment" or "therapy" of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down, or preventing the onset, progression, development, severity, or recurrence of a symptom, complication, condition, or biochemical indicia associated with a disease. In some embodiments, the disease is cancer. As used herein, the terms "treatment" and "treating" when referring, e.g., to the treatment of a cancer, are not intended to be absolute terms. For example, “treatment of cancer” and “treating cancer”, as used in a clinical setting, is intended to include obtaining beneficial or desired clinical results and can include an improvement in the condition of a subject having cancer. Beneficial or desired clinical results include, but are not limited to, one or more of the following: reducing the proliferation of (or destroying) neoplastic or cancerous cells, inhibiting metastasis of neoplastic cells, a decrease in metastasis in a subject, shrinking or decreasing the size of a tumor, change in the growth rate of one or more tumor(s) in a subject, an increase in the period of remission for a subject (e.g., as compared to the one or more metric(s) in a subject having a similar cancer receiving no treatment or a different treatment, or as compared to the one or more metric(s) in the same subject prior to treatment), decreasing symptoms resulting from a disease, increasing the quality of life of those suffering from a disease (e.g., assessed using FACT-G or EORTC- QLQC30), decreasing the dose of other medications required to treat a disease, delaying the progression of a disease, and / or prolonging survival of subjects having a disease.

[0050] The term "prophylactic" or “prophylactically” refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of protectingor preventing a disease or condition from developing or at least not developing fully (e.g., to reduce the symptoms or severity of the disease or condition) such as in the development of a side effect (e.g., diarrhea).

[0051] A "subject" includes any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human. The terms "subject" and "patient" and “individual” are used interchangeably herein.

[0052] An “effective amount” or "therapeutically effective amount" or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.

[0053] By way of example, an "anti-cancer agent" promotes cancer regression in a subject. In some embodiments, a therapeutically effective amount of the drug promotes cancer regression to the point of eliminating the cancer. "Promoting cancer regression" means that administering an effective amount of the drug, alone or in combination with an anti-cancer agent, results in a reduction in tumor growth or size, necrosis of the tumor, a decrease in severity of at least one disease symptom, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. In addition, the terms "effective" and "effectiveness" with regard to a treatment includes both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of the drug to promote cancer regression in the patient. Physiological safety refers to the level of toxicity or other adverse physiological effects at the cellular, organ and / or organism level (adverse effects) resulting from administration of the drug.

[0054] The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a formulation, and / or the mammal being treated therewith.

[0055] As used herein, the term “pharmaceutically acceptable carrier” refers to a substance that aids the administration of an active agent to a cell, an organism, or a subject. “Pharmaceutically acceptable carrier” refers to a carrier or excipient that can be included in the compositions of the disclosure and that causes no significant adverse toxicological effect on the subject. Non-limiting examples of pharmaceutically acceptable carriers include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings,sweeteners, flavors and colors, liposomes, dispersion media, microcapsules, cationic lipid carriers, isotonic and absorption delaying agents, and the like. The carrier may also be substances for providing the formulation with stability, sterility and isotonicity (e.g., antimicrobial preservatives, antioxidants, chelating agents and buffers), for preventing the action of microorganisms (e.g. antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid and the like) or for providing the formulation with an edible flavor etc. In some instances, the carrier is an agent that facilitates the delivery of a small molecule drug or antibody to a target cell or tissue. One of skill in the art will recognize that other pharmaceutical carriers are useful in the present disclosure.

[0056] The phrase "pharmaceutically acceptable salt" as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the disclosure. Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bi sulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gen isinate, fumarate, gluconate, g!ucuronate, saccbarate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 4,4’ -methyl ene-bis -(2- hydroxy-3-napbthoate)) salts, alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and / or one or more counter ion. II. Methods

[0057] Certain aspects of the present disclosure relate to methods for reducing the likelihood and / or severity of one or more adverse events (e.g., peripheral neuropathy, anemia, and / or neutropenia) in an individual being treated with an antibody-drug conjugate (ADC). In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. In some embodiments, administration of the ADC results in decreased likelihood and / or severity of one or more adverse events (e.g., peripheral neuropathy, anemia, and / or neutropenia) in the individual, e.g., as compared to likelihood and / or severity of the one or more adverse events (e.g., peripheral neuropathy, anemia, and / or neutropenia) in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0058] In some embodiments, peripheral neuropathy as used herein is characterized by neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, and / or parasthesia. In some embodiments, peripheral motor neuropathy is characterized by damage or dysfunction of the peripheral motor nerves. In some embodiments, peripheral sensorial neuropathy is characterized by damage or dysfunction of the peripheral sensory nerves. In some embodiments, parasthesia is characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and / or warmth. Methods for assessing peripheral neuropathy are known in the art.

[0059] In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in decreased likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in the individual, e.g., as compared to likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0060] In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of peripheral neuropathy in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%, e.g., as compared to the likelihood of peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of grade 3 or grade 4 peripheral neuropathy in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%, e.g., as compared to the likelihood of grade 3 or grade 4 peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the administration does not result in grade 3 or grade 4 peripheral neuropathy in the individual.

[0061] In some embodiments, neutropenia as used herein is characterized by a decrease in neutrophil count in a blood specimen. In some embodiments, neutropenia refers to less than 1500 neutrophils / mm3 or less than 1.5x109neutrophils / L, e.g., in a blood specimen. In some embodiments, grade 3 neutropenia refers to 500-1000 neutrophils / mm3 or 0.5-1.0x109neutrophils / L, e.g., in a blood specimen. In some embodiments, grade 4 neutropenia refers to less than 500 neutrophils / mm3 or less than 0.5x109neutrophils / L, e.g., in a blood specimen.

[0062] In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in decreased likelihood and / or severity of neutropenia and / or neutrophil count decrease in the individual, e.g., as compared to likelihood and / or severity of neutropenia and / or neutrophil count decrease in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, the neutropenia does not comprise febrile neutropenia.

[0063] In some embodiments, anemia as used herein is characterized by reduction in the amount of hemoglobin (Hgb) in blood (e.g., in 100mL of blood). Anemia may be accompanied by one or more of pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. In some embodiments, anemia refers to Hgb of less than 10.0g / dL, 6.2mmol / L, or 100g / L, e.g., in blood. In some embodiments, grade 3 anemia refers to Hgb of less than 8.0g / dL, 4.9mmol / L, or 80g / L, e.g., in blood.

[0064] In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of anemia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, e.g., as compared to the likelihood of anemia in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of grade 3 or grade 4 anemia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, e.g., as compared to the likelihood of grade 3 or grade 4 anemia in an individual administered an ADC comprising a human Fc region with wild-type effector function

[0065] In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of neutropenia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, e.g., as compared to the likelihood of neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function. In some embodiments, administration of an ADC whose antibody component comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function results in a reduction in the likelihood of grade 3 or grade 4 neutropenia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, e.g., as compared to the likelihood of grade 3 or grade 4 neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0066] In some embodiments, an adverse event of the present disclosure (e.g., peripheral neuropathy, anemia, and / or neutropenia) comprises grade 3 or grade 4 adverse event (e.g., grade 3 orgrade 4 peripheral neuropathy, anemia, and / or neutropenia). In some embodiments, a grade 3 adverse event refers to one that is severe or medically significant but not immediately life-threatening, indicated for hospitalization or prolonging of hospitalization, disabling, and / or limiting daily life activities. In some embodiments, a grade 4 adverse event refers to one that is life-threatening and / or indicated for urgent intervention.

[0067] Other aspects of the present disclosure relate to methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. In some embodiments, the ADC is administered to the individual at an increased amount and / or at a higher frequency, e.g., as compared to amount and / or frequency of dosing in an individual administered an ADC comprising a human Fc region with wild-type effector function.

[0068] In some embodiments, the ADC is administered to the individual at an increased amount, e.g., as compared to an amount of an ADC comprising a human Fc region with wild-type effector function administered to the individual.

[0069] In some embodiments, the ADC is administered to the individual at an increased frequency, e.g., as compared to a frequency of administration of an ADC comprising a human Fc region with wild-type effector function to the individual.

[0070] In some embodiments, the ADC is administered to the individual at an increased amount as compared to a reference amount. In some embodiments, administration of the ADC at the increased amount does not increase likelihood and / or severity of one or more adverse events in the individual, e.g., as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference amount. For example, the reference amount may refer to a dosing amount that is approved for use or in clinical testing for a comparator ADC, e.g., comprising an antibody component that binds the same antigen (e.g., the same variable domain sequence(s)), the same linker moiety, and / or the same drug payload, but comprising a human Fc region with wild-type effector function.

[0071] In some embodiments, the ADC is administered to the individual at an increased frequency as compared to a reference frequency. In some embodiments, administration of the ADC at the increased frequency does not increase likelihood and / or severity of one or more adverse events in the individual, e.g., as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference frequency. For example, the reference frequency may refer to a dosing frequency that is approved for use or in clinical testing for a comparator ADC, e.g., comprising an antibody component that binds the same antigen (e.g., the same variable domain sequence(s)), the same linkermoiety, and / or the same drug payload, but comprising a human Fc region with wild-type effector function.

[0072] In some embodiments, an adverse event of the present disclosure refers to peripheral neuropathy, anemia, or neutropenia, e.g., grade 3 or grade 4 peripheral neuropathy, anemia, or neutropenia.

[0073] In some embodiments, the individual has or has been diagnosed with cancer. In some embodiments, the individual is being treated for cancer (e.g., with the ADC of the present disclosure). In some embodiments, the cancer is melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, or cervical cancer. In some embodiments, the cancer is a hematopoietic cancer such as, for example, lymphoma (Hodgkin Lymphoma or Non-Hodgkin Lymphoma) and leukemia and solid tumors. Examples of hematopoietic cancers include, follicular lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, acute myeloblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, and multiple myeloma. Examples of solid tumors include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, and retinoblastoma. Antibodies

[0074] In some embodiments, an ADC of the present disclosure comprises an antibody comprising a human Fc region with reduced or eliminated effector function.

[0075] In some embodiments, an antibody effector function can refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include without limitation: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cellsurface receptors (e.g., B cell receptors); and B cell activation. Assays for measuring effector function are known in the art and include, without limitation, in vitro and / or in vivo cytotoxicity assays to confirm the reduction / depletion of CDC ((see, e.g., Cragg, M.S. et al., Blood 101:1045-1052 (2003)); and / or ADCC activities (see, e.g., Hellstrom, I. et al. Proc. Nat’l Acad. Sci. USA 83:7059- 7063 (1986)) and biochemical assays to measure Fc receptor binding (see, e.g., Shields et al., J. Biol. Chem.9(2): 6591-6604 (2001)). In some embodiments, antibody effector function can be mediated by one or more effector cells, e.g., cells that express one or more FcRs and perform effector functions, e.g., ADCC. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils. The effector cells may be isolated from a native source, e.g., from blood.

[0076] In some embodiments, an ADC of the present disclosure comprises an antibody having a human Fc region that has reduced or eliminated binding to one or more human Fc receptor(s), e.g., as compared to binding of a human Fc region with wild-type effector function to the one or more human Fc receptor(s). In some embodiments, the one or more human Fc receptor(s) are human FcγRI, FcγRII, and / or FcγRIII Fc receptors. In some embodiments, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc^RI, Fc^RII, and Fc^RIII subclasses, including allelic variants and alternatively spliced forms of those receptors. Fc^RII receptors include Fc^RIIA (an "activating receptor") and Fc^RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. The term "Fc receptor" or “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus. Binding to human FcRn in vivo and serum half life of human FcRn high affinity binding polypeptides can be assayed, e.g., in transgenic mice or transfected human cell lines expressing human FcRn, or in primates to which the polypeptides with a variant Fc region are administered. WO 2000 / 42072 describes antibody variants with improved or diminished binding to FcRs. See also, e.g., Shields et al. J. Biol. Chem.9(2):6591-6604 (2001).

[0077] In some embodiments, an ADC of the present disclosure comprises an antibody having a human Fc region that has reduced or eliminated binding to complement C1q, e.g., as compared to binding of a human Fc region with wild-type effector function to complement C1q.

[0078] In some embodiments, an ADC of the present disclosure comprises an antibody having a human Fc region (e.g., a human IgG1 or IgG2 Fc region) that has one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human Fc region (e.g., a wild-type human IgG1 or IgG2). Exemplary IgG1 mutations and positions where mutations can be introduced into an IgG1 Fc region can be found, e.g., in Armour, K.L. et al. (2003) Mol. Immunol. 40:585-593 and Lazar, G.A. et al. (2006) Proc. Natl. Acad. Sci. USA 103:4005-4010. Exemplary IgG2 mutations and positions where mutations can be introduced into an IgG2 Fc region can be found, e.g., in US PG Pub. No. US20170204193.

[0079] In some embodiments, an ADC of the present disclosure is modified to comprise a wild- type or mutated human Fc region (e.g., a human IgG4 Fc region) of one isotype that has reduced or absent effector function, as compared to effector function of the original Fc region. For example, a human IgG1 Fc region can be swapped with a human IgG4 Fc region (which has reduced or absent effector function) in an ADC disclosed herein in order to reduce or eliminate effector function. In some embodiments, the human IgG4 Fc region is a wild-type human IgG4 Fc region, or it can comprise one or more mutations. Exemplary IgG4 mutations and positions where mutations can be introduced into an IgG4 Fc region can be found, e.g., in Armour, K.L. et al. (2003) Mol. Immunol. 40:585-593 and Angal, S. et al. (1993) Mol Immunol 30, 105–108. In some embodiments, a single amino acid substitution (S228P according to Kabat numbering; designated IgG4Pro) may be introduced into the hinge region to abolish the heterogeneity observed in recombinant IgG4 antibody.

[0080] In some embodiments, an ADC of the present disclosure comprises an antibody having a human IgG1 Fc region comprising an amino acid substitution at one or more of position(s) L234, L235, G236, and / or G237, numbering according to EU index. In some embodiments, an ADC of the present disclosure comprises an antibody having a human Fc region a human IgG1 Fc region comprising amino acid substitution(s) at position(s) L234 and / or L235, numbering according to EU index. In some embodiments, an ADC of the present disclosure comprises an antibody having a human IgG1 Fc region comprising L234A and L235A substitutions, numbering according to EU index.

[0081] In some embodiments, an ADC of the present disclosure comprises an antibody having a human IgG1 Fc region comprising one of the following sets of mutations (numbering according to EU index): L234A / L235A / P329G, L234A / L235A / G236R, L234A / G236R, L234A / L235S / G236R, L234A / L235T / G236R, L234D / L235H / G236R, L234D / L235K / G236R, L234D / G236R, L234D / L235Q / G236R, L234D / L235S / G236R, L234D / L235T / G236R, L234E / L235D / G236R, L234E / L235H / G236R, L234E / L235I / G236R, L234E / G236R, L234E / L235V / G236R, L234G / L235H / G236R, L234G / L235Q / G236R, L234G / L235S / G236R, L234H / L235I / G236R, L234H / L235S / G236R, L234K / L235Q / G236R, L234K / L235R / G236R, L234K / L235S / G236R, L234K / L235T / G236R, L234K / L235V / G236R, L234Q / L235A / G236R, L234Q / L235D / G236R, L234Q / L235H / G236R, L234Q / G236R, L234Q / L235Q / G236R, L234Q / L235R / G236R, L234Q / L235S / G236R, L234Q / L235T / G236R, L234Q / L235V / G236R, L234R / L235D / G236R, L234R / L235E / G236R, L234R / L235H / G236R, L234R / L235I / G236R, L234R / L235K / G236R, L234R / G236R, L234R / L235Q / G236R, L234R / L235R / G236R, L234R / L235T / G236R, L234S / L235D / G236R, L234S / L235E / G236R, L234S / L235G / G236R, L234S / L235H / G236R, L234S / L235I / G236R, L234S / G236R, L234S / L235R / G236R, L234S / L235T / G236R, L234S / L235V / G236R, L234T / L235A / G236R, L234T / L235D / G236R, L234T / L235H / G236R, L234T / L235I / G236R, L234T / L235K / G236R, L234T / G236R, L234T / L235Q / G236R,L234T / L235R / G236R, L234T / L235S / G236R, L234T / L235T / G236R, L234T / L235V / G236R, L234A / L235A, L234A / L235A / P329G, N297Q, G236R / L328R, L234A / G237A, L234A / L235E, L235V / F243L / R292P / Y300L / P396L, D265A / P329A, L234A / L235A / K322A, L234F / L235E / P331S, L234F / L235Q / K322Q, L234A / L235A / G237A / P238S / H268A / A330S / P331S, E233P / L234V / L235A / G236x / A327G / A330S / P331S, L235A / G236R, L235S / G236R, G236R, L235G / G236R, or L234A / L235A / P329G.

[0082] In some embodiments, the antibody binds to human PD-L1. In some embodiments, the antibody comprises heavy chain CDR sequences of SEQ ID NOs: 13-15 and light chain CDR sequences of SEQ ID NOs: 16-18. In some embodiments, the antibody comprises a heavy chain variable region sequence of SEQ ID NO: 11 and a light chain variable region sequence of SEQ ID NO: 12. In some embodiments, the antibody comprises a light chain of SEQ ID NO: 9 and a heavy chain of SEQ ID NO: 10. In some embodiments, the antibody comprises heavy chain CDR sequences of SEQ ID NOs: 3-5 and light chain CDR sequences of SEQ ID NOs: 6-8. In some embodiments, the antibody includes a heavy chain variable region sequence having at least 80% sequence identity to SEQ ID NO: 11 and a light chain variable region sequence having at least 80% sequence identity to SEQ ID NO: 12. In some embodiments, the antibody includes a heavy chain variable region sequence having at least 90% sequence identity to SEQ ID NO: 11 and a light chain variable region sequence having at least 90% sequence identity to SEQ ID NO: 12. In some embodiments, the antibody includes a heavy chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 11 and a light chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 12. In some embodiments, the antibody includes a heavy chain variable region sequence of SEQ ID NO: 11 and a light chain variable region sequence of SEQ ID NO: 12. In some embodiments, the antibody includes a light chain of SEQ ID NO: 9 and a heavy chain of SEQ ID NO: 10.

[0083] In some embodiments, the antibody binds to human B7-H4, CD19, CD30, CD33, CD70, CD228, ITGB6 (integrin beta 6), Nectin-4, TF (tissue factor), Her2, STn, ALPP, or LIV-1.

[0084] Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, or chimeric human-mouse (or other species) monoclonal antibodies. The antibodies include full-length antibodies and antigen binding fragments thereof. Human monoclonal antibodies can be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA.80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; and Olsson et al., 1982, Meth. Enzymol.92:3-16).

[0085] An antibody useful for inclusion into the Ligand-Drug conjugates of the disclosure is an intact antibody or a functionally active fragment, derivative, or analog of an antibody, wherein the antibody or fragment thereof is capable of immunospecific binding to target cells (e.g., cancer cell antigens, viral antigens, or microbial antigens) or other antibodies that are bound to tumor cells or matrix. In this regard, “functionally active” means that the fragment, derivative, or analog is able toimmunospecifically bind to target cells. To determine which CDR sequences bind the antigen, synthetic peptides containing the CDR sequences in some embodiments are used in binding assays with the antigen by a binding assay method known in the art (e.g., the BiacoreTMassay) (See, e.g., Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md; Kabat E et al., 1980, J. Immunology 125(3):961-969).

[0086] Other useful Ligands include fragments of antibodies such as, but not limited to, F(ab’)2 fragments, Fab fragments, Fvs, single chain antibodies, diabodies, triabodies, tetrabodies, scFv, scFv- FV, or any other molecule with the same specificity as the antibody.

[0087] Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which in some embodiments are made using standard recombinant DNA techniques, are useful antibodies. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as for example, those having a variable region derived from a murine monoclonal and human immunoglobulin constant regions. (See, e.g., U.S. Patent No.4,816,567; and U.S. Patent No.4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., U.S. Patent No.5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies in some embodiments are produced by recombinant DNA techniques known in the art, for example using methods described in International Publication No. WO 87 / 02671; European Patent Publication No.0184187; European Patent Publication No.0171 496; European Patent Publication No.0173494; International Publication No. WO 86 / 01533; U.S. Patent No.4,816,567; Berter et al., Science (1988) 240: 1041-1043; Liu et al., Proc. Nat'l. Acad. Sci. USA (1987) 84: 3439-3443; Liu et al., J. Immunol. (1987) 139: 3521-3526; Sun et al., Proc. Natl. Acad. Sci. USA (1987) 84: 214-218; Nishimura et al., Cancer. Res. (1987) 47: 999-1005; Wood et al., Nature (1985) 314: 446-449; Shaw et al., J. Natl. Cancer Inst. (1988) 80: 1553-1559; Morrison, Science (1985) 229: 1202-1207; Oi et al., BioTechniques (1986) 4: 214-221; U.S. Patent No. 5,225,539; Jones et al., Nature (1986) 321: 552-525; Verhoeyan et al., Science (1988) 239: 1534- 1536; and Beidler et al., J. Immunol. (1988) 141: 4053-4060; each of which is incorporated herein by reference in its entirety.

[0088] Completely human antibodies in some instances (e.g., when immunogenicity to a non-human or chimeric antibody may occur) are more desirable and in some embodiments are produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which are capable of expressing human heavy and light chain genes.

[0089] Antibodies include analogs and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retainits antigen binding immunospecificity. For example, but not by way of limitation, derivatives and analogs of the antibodies include those that have been further modified, e.g., by glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivitization by known protecting / blocking groups, proteolytic cleavage, linkage to a cellular antibody unit or other protein, etc. In some embodiments one or more of those numerous chemical modifications are carried out by known techniques including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis in the presence of tunicamycin, etc. In other embodiments, an analog or derivative of an antibody contains one or more unnatural amino acids, which is sometimes in combination with one or more of the above-described chemical modifications.

[0090] In some embodiments the antibody has one or more modifications (e.g., substitutions, deletions or additions) in amino acid residues that interact with Fc receptors. Those include modifications in amino acid residues identified as involved in the interaction between the anti-Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97 / 34631, which is incorporated herein by reference in its entirety).

[0091] In some embodiments, antibodies immunospecific for a cancer cell antigen are obtained commercially or produced by a method known to one of skill in the art such as, recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a cancer cell antigen is sometimes obtained, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.

[0092] In a specific embodiment, a known antibody for the treatment of cancer is used.

[0093] In another specific embodiment, an antibody for the treatment of an autoimmune disease is used in accordance with the compositions and methods of the invention.

[0094] In certain embodiments, useful antibodies bind to a receptor or a receptor complex expressed on an activated lymphocyte. That receptor or receptor complex, in some embodiments, is an immunoglobulin gene superfamily member, a TNF receptor superfamily member, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein.

[0095] In some enbodiments, the antibody that is incorporated into a STING Agonist Conjugate will specifically bind B7-H4, CD19, CD30, CD33, CD70, CD228, ITGB6 (integrin beta 6), Nectin-4, TF (tissue factor), Her2, STn, ALPP, or LIV-1.

[0096] Exemplary antigens are provided below. Exemplary antibodies that bind the indicated antigen are shown in parentheses.

[0097] In some embodiments, the antigen is a tumor-associated antigen. In some embodiments, the tumor-associated antigen is a transmembrane protein. For example, the following antigens are transmembrane proteins: ANTXR1, BAFF-R, CA9 (exemplary antibodies include girentuximab), CD147 (exemplary antibodies include gavilimomab and metuzumab), CD19, CD20 (exemplaryantibodies include rituximab, divozilimab and ibritumomab), CD274 also known as PD-L1 (exemplary antibodies include adebrelimab, atezolizumab, garivulimab, durvalumab, and avelumab), CD30 (exemplary antibodies include iratumumab and brentuximab), CD33 (exemplary antibodies include lintuzumab), CD352, CD45 (exemplary antibodies include apamistamab), CD47 (exemplary antibodies include letaplimab and magrolimab), CLPTM1L, DLL3, DPP4, EGFR, ERVMER34-1, FASL, FSHR, FZD5, FZD8, GUCY2C (exemplary antibodies include indusatumab), IFNAR1 (exemplary antibodies include anifrolumab), IFNAR2, LMP2, MLANA, SIT1, TLR2 / 4 / 1 (exemplary antibodies include tomaralimab), TM4SF5, TMEM132A, TMEM40, UPK1B, VEGF, and VEFGR2 (exemplary antibodies include gentuximab).

[0098] In some embodiments, the tumor-associated antigen is a transmembrane transport protein. For example, the following antigens are transmembrane transport proteins: ASCT2 (exemplary antibodies include idactamab), MFSD13A, Mincle, NaPi2b, NOX1, SLC10A2, SLC12A2, SLC17A2, SLC38A1, SLC39A5, SLC39A6 also known as LIV1 (exemplary antibodies include ladiratuzumab), SLC44A4, SLC6A15, SLC6A6, SLC7A11, and SLC7A5.

[0099] In some embodiments, the tumor-associated antigen is a transmembrane or membrane- associated glycoprotein. For example, the following antigens are transmembrane or membrane- associated glycoproteins: CA-125, CA19-9, CAMPATH-1 / CD52 (exemplary antibodies include alemtuzumab), carcinoembryonic antigen / CEA (exemplary antibodies include arcitumomab), CEACAM5 (exemplary antibodies include cergutuzumab and labetuzumab), CD112, CD155, CD24, CD247, CD37 (exemplary antibodies include lilotomab), CD38 (exemplary antibodies include felzartamab), CD3D, CD3E (exemplary antibodies include foralumab and teplizumab), CD3G, CD96, CDCP1, CDH17, CDH3, CDH6, CEACAM1, CEACAM6, CLDN1, CLDN16, CLDN18.1, CLDN18.2 (exemplary antibodies include zolbetuximab), CLDN19, CLDN2, CLEC12A (exemplary antibodies include tepoditamab), DPEP1, DPEP3, DSG2, endosialin (exemplary antibodies include ontuxizumab), ENPP1, EPCAM (exemplary antibodies include adecatumumab), FN, FN1, Gp100, GPA33, gpNMB (exemplary antibodies include glembatumumab), ICAM1, L1CAM, LAMP1, MELTF also known as CD228, NCAM1, Nectin-4 (exemplary antibodies include enfortumab), PDPN, PMSA, PROM1, PSCA, PSMA, Siglecs 1-16, SIRPa, SIRPg, TACSTD2, TAG-72, Tenascin, Tissue Factor also known as TF (exemplary antibodies include tisotumab), and ULBP1 / 2 / 3 / 4 / 5 / 6.

[0100] In some embodiments, the tumor-associated antigen is a transmembrane or membrane- associated receptor kinase. For example, the following antigens are transmembrane or membrane- associated receptor kinases: ALK, Axl (exemplary antibodies include tilvestamab), BMPR2, DCLK1, DDR1, EPHA receptors, EPHA2, ERBB2 also known as HER2 (exemplary antibodies include trastuzumab, pertuzumab, disitamab / RC48, and margetuximab), ERBB3, FLT3, PDGFR-B (exemplary antibodies include rinucumab), PTK7 (exemplary antibodies include cofetuzumab), RET, ROR1 (exemplary antibodies include cirmtuzumab), ROR2, ROS1, and Tie3.

[0100] In some embodiments, the tumor-associated antigen is a membrane-associated or membrane- localized protein. For example, the following antigens are membrane-associated or membrane- localized proteins: ALPP, ALPPL2, ANXA1, FOLR1 (exemplary antibodies include farletuzumab), IL13Ra2, IL1RAP (exemplary antibodies include nidanilimab), NT5E, OX40, Ras mutant, RGS5, RhoC, SLAMF7 (exemplary antibodies include elotuzumab), and VSIR.

[0101] In some embodiments, the tumor-associated antigen is a transmembrane G-protein coupled receptor (GPCR). For example, the following antigens are GPCRs: CALCR, CD97, GPR87, and KISS1R.

[0102] In some embodiments, the tumor-associated antigen is cell-surface-associated or a cell- surface receptor. For example, the following antigens are cell-surface-associated and / or cell-surface receptors: B7-DC, BCMA, CD137, CD244, CD3 (exemplary antibodies include otelixizumab and visilizumab), CD48, CD5 (exemplary antibodies include zolimomab), CD70 (exemplary antibodies include cusatuzumab and vorsetuzumab), CD74 (exemplary antibodies include milatuzumab), CD79A, CD262 / DR5 (exemplary antibodies include tigatuzumab), DR4 (exemplary antibodies include mapatumumab), FAS, FGFR1, FGFR2 (exemplary antibodies include aprutumab), FGFR3 (exemplary antibodies include vofatamab), FGFR4, GITR (exemplary antibodies include ragifilimab), HAVCR2, HLA-E, HLA-F, HLA-G, LAG-3 (exemplary antibodies include encelimab), LY6G6D, LY9, MICA, MICB, MSLN, MUC1, MUC5AC, NY-ESO-1, OY-TES1, PVRIG, Sialyl-Thomsen- Nouveau Antigen, Sperm protein 17, TNFRSF12, and uPAR.

[0103] In some embodiments, the tumor-associated antigen is a chemokine receptor or cytokine receptor. For example, the following antigens are chemokine receptors or cytokine receptors: CD115 (exemplary antibodies include axatilimab, cabiralizumab, and emactuzumab), CD123, CXCR4 (exemplary antibodies include ulocuplumab), IL-21R, and IL-5R (exemplary antibodies include benralizumab).

[0104] In some embodiments, the tumor-associated antigen is a co-stimulatory or co-inhibitory, surface-expressed protein. For example, the following antigens are co-stimulatory or co-inhibitory, surface-expressed proteins: B7-H3 (exemplary antibodies include enoblituzumab and omburtamab), B7-H4, B7-H6, and B7-H7.

[0105] In some embodiments, the tumor-associated antigen is a transcription factor or a DNA- binding protein. For example, the following antigens are transcription factors: ETV6-AML, MYCN, PAX3, PAX5, and WT1. The following protein is a DNA-binding protein: BORIS.

[0106] In some embodiments, the tumor-associated antigen is an integral membrane protein. For example, the following antigens are integral membrane proteins: SLITRK6 (exemplary antibodies include sirtratumab), UPK2, and UPK3B.

[0107] In some embodiments, the tumor-associated antigen is an integrin. For example, the following antigens are integrin antigens: integrin alpha v beta 6, ITGAV (exemplary antibodies include abituzumab), ITGB6, and ITGB8.

[0108] In some embodiments, the tumor-associated antigen is a glycolipid. For example, the following are glycolipid antigens: FucGM1, GD2 (exemplary antibodies include dinutuximab), GD3 (exemplary antibodies include mitumomab), GloboH, GM2, and GM3 (exemplary antibodies include racotumomab).

[0109] In some embodiments, the tumor-associated antigen is a cell-surface hormone receptor. For example, the following antigens are cell-surface hormone receptors: AMHR2 and androgen receptor.

[0110] In some embodiments, the tumor-associated antigen is a transmembrane or membrane- associated protease. For example, the following antigens are transmembrane or membrane-associated proteases: ADAM12, ADAM9, TMPRSS11D, and metalloproteinase.

[0111] In some embodiments, the tumor-associated antigen is aberrantly expressed in individuals with cancer. For example, the following antigens may be aberrantly expressed in individuals with cancer: AFP, AGR2, AKAP-4, ARTN, BCR-ABL, C5 complement, CCNB1, CSPG4, CYP1B1, De2- 7 EGFR, EGF, Fas-related antigen 1, FBP, G250, GAGE, HAS3, HPV E6, HPV E7, hTERT, IDO1, LCK, Legumain, LYPD1, MAD-CT-1, MAD-CT-2, MAGEA3, MAGEA4, MAGEC2, MerTk, ML- IAP, NA17, NY-BR-1, p53, p53 mutant, PAP, PLAVI, polysialic acid, PR1, PSA, Sarcoma translocation breakpoints, SART3, sLe, SSX2, Survivin, Tn, TRAIL, TRAIL1, TRP-2, and XAGE1.

[0112] In some embodiments, the antigen is an immune-cell-associated antigen. In some embodiments, the immune-cell-associated antigen is a transmembrane protein. For example, the following antigens are transmembrane proteins: BAFF-R, CD163, CD19, CD20 (exemplary antibodies include rituximab, ocrelizumab, divozilimab; ibritumomab), CD25 (exemplary antibodies include basiliximab), CD274 also known as PD-L1 (exemplary antibodies include adebrelimab, atezolizumab, garivulimab, durvalumab, and avelumab), CD30 (exemplary antibodies include iratumumab and brentuximab), CD33 (exemplary antibodies include lintuzumab), CD352, CD45 (exemplary antibodies include apamistamab), CD47 (exemplary antibodies include letaplimab and magrolimab), CTLA4 (exemplary antibodies include ipilimumab), FASL, IFNAR1, IFNAR2, LAYN, LILRB2, LILRB4, PD-1 (exemplary antibodies include nivolumab, pembrolizumab, balstilimab, budigalimab, geptanolimab, toripalimab, and pidilizumab), SIT1, and TLR2 / 4 / 1 (exemplary antibodies include tomaralimab).

[0113] In some embodiments, the immune-cell-associated antigen is a transmembrane transport protein. For example, Mincle is a transmembrane transport protein.

[0114] In some embodiments, the immune-cell-associated antigen is a transmembrane or membrane- associated glycoprotein. For example, the following antigens are transmembrane or membrane- associated glycoproteins: CD112, CD155, CD24, CD247, CD28, CD30L, CD37 (exemplary antibodies include lilotomab), CD38 (exemplary antibodies include felzartamab), CD3D, CD3E (exemplary antibodies include foralumab and teplizumab), CD3G, CD44, CLEC12A (exemplary antibodies include tepoditamab), DCIR, DCSIGN, Dectin 1, Dectin 2, ICAM1, LAMP1, Siglecs 1-16, SIRPa, SIRPg, and ULBP1 / 2 / 3 / 4 / 5 / 6.

[0115] In some embodiments, the immune-cell-associated antigen is a transmembrane or membrane- associated receptor kinase. For example, the following antigens are transmembrane or membrane- associated receptor kinases: Axl (exemplary antibodies include tilvestamab) and FLT3.

[0116] In some embodiments, the immune-cell-associated antigen is a membrane-associated or membrane-localized protein. For example, the following antigens are membrane-associated or membrane-localized proteins: CD83, IL1RAP (exemplary antibodies include nidanilimab), OX40, SLAMF7 (exemplary antibodies include elotuzumab), and VSIR.

[0117] In some embodiments, the immune-cell-associated antigen is a transmembrane G-protein coupled receptor (GPCR). For example, the following antigens are GPCRs: CCR4 (exemplary antibodies include mogamulizumab-kpkc), CCR8, and CD97.

[0118] In some embodiments, the immune-cell-associated antigen is cell-surface-associated or a cell- surface receptor. For example, the following antigens are cell-surface-associated and / or cell-surface receptors: B7-DC, BCMA, CD137, CD2 (exemplary antibodies include siplizumab), CD244, CD27 (exemplary antibodies include varlilumab), CD278 (exemplary antibodies include feladilimab and vopratelimab), CD3 (exemplary antibodies include otelixizumab and visilizumab), CD40 (exemplary antibodies include dacetuzumab and lucatumumab), CD48, CD5 (exemplary antibodies include zolimomab), CD70 (exemplary antibodies include cusatuzumab and vorsetuzumab), CD74 (exemplary antibodies include milatuzumab), CD79A, CD262 / CD5 (exemplary antibodies include tigatuzumab), DR4 (exemplary antibodies include mapatumumab), GITR (exemplary antibodies include ragifilimab), HAVCR2, HLA-DR, HLA-E, HLA-F, HLA-G, LAG-3 (exemplary antibodies include encelimab), MICA, MICB, MRC1, PVRIG, Sialyl-Thomsen-Nouveau Antigen, TIGIT (exemplary antibodies include etigilimab), Trem2, and uPAR.

[0119] In some embodiments, the immune-cell-associated antigen is a chemokine receptor or cytokine receptor. For example, the following antigens are chemokine receptors or cytokine receptors: CD115 (exemplary antibodies include axatilimab, cabiralizumab, and emactuzumab), CD123, CXCR4 (exemplary antibodies include ulocuplumab), IL-21R, and IL-5R (exemplary antibodies include benralizumab).

[0120] In some embodiments, the immune-cell-associated antigen is a co-stimulatory or co- inhibitory, surface-expressed protein. For example, the following antigens are co-stimulatory or co- inhibitory, surface-expressed proteins: B7-H3 (exemplary antibodies include enoblituzumab and omburtamab), B7-H4, B7-H6, and B7-H7.

[0121] In some embodiments, the immune-cell-associated antigen is a peripheral membrane protein. For example, the following antigens are peripheral membrane proteins: B7-1 (exemplary antibodies include galiximab) and B7-2.

[0122] In some embodiments, the immune-cell-associated antigen is aberrantly expressed in individuals with cancer. For example, the following antigens may be aberrantly expressed in individuals with cancer: C5 complement, IDO1, LCK, MerTk, and Tyrol.

[0123] In some embodiments, the antigen is a stromal-cell-associated antigen. In some embodiments, the stromal-cell-associated antigen is a transmembrane or membrane-associated protein. For example, the following antigens are transmembrane or membrane-associated proteins: FAP (exemplary antibodies include sibrotuzumab), IFNAR1, and IFNAR2.

[0124] In some embodiments, the antigen is CD30. In some embodiments, the antibody is an antibody or antigen-binding fragment that binds to CD30, such as described in International Patent Publication No. WO 02 / 43661. In some embodiments, the anti-CD30 antibody is cAC10, which is described in International Patent Publication No. WO 02 / 43661. cAC10 is also known as brentuximab. In some embodiments, the anti-CD30 antibody comprises the CDRs of cAC10. In some embodiments, the CDRs are as defined by the Kabat numbering scheme. In some embodiments, the CDRs are as defined by the Chothia numbering scheme. In some embodiments, the CDRs are as defined by the IMGT numbering scheme. In some embodiments, the CDRs are as defined by the AbM numbering scheme. In some embodiments, the anti-CD30 antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1101, 1102, 1103, 1104, 1105, and 1106, respectively. In some embodiments, the anti-CD30 antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1107 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1108. In some embodiments, the anti-CD30 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1109 or SEQ ID NO: 1110 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1111.

[0125] In some embodiments, the antigen is CD70. In some embodiments, the antibody is an antibody or antigen-binding fragment that binds to CD70, such as described in International Patent Publication No. WO 2006 / 113909. In some embodiments, the antibody is a h1F6 anti-CD70 antibody, which is described in International Patent Publication No. WO 2006 / 113909. h1F6 is also known as vorsetuzumab. In some embodiments, the anti-CD70 antibody comprises a heavy chain variable region comprising the three CDRs of SEQ ID NOs: 279, 280, and 281 and a light chain variable region comprising the three CDRs of SEQ ID NOs: 282, 283, and 284. In some embodiments, the CDRs are as defined by the Kabat numbering scheme. In some embodiments, the CDRs are as defined by the Chothia numbering scheme. In some embodiments, the CDRs are as defined by the IMGT numbering scheme. In some embodiments, the CDRs are as defined by the AbM numbering scheme. In some embodiments, the anti-CD70 antibody comprises a heavy chain variable region comprisingan amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 285 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286. In some embodiments, the anti-CD70 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 287 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 288.

[0126] In some embodiments, the antigen is interleukin-1 receptor accessory protein (IL1RAP). IL1RAP is a co-receptor of the IL1 receptor (IL1R1) and is required for interleukin-1 (IL1) signaling. IL1 has been implicated in the resistance to certain chemotherapy regimens. IL1RAP is overexpressed in various solid tumors, both on cancer cells and in the tumor microenvironment, but has low expression on normal cells. IL1RAP is also overexpressed in hematopoietic stem and progenitor cells, making it a candidate to target for chronic myeloid leukemia (CML). IL1RAP has also been shown to be overexpressed in acute myeloid leukemia (AML). Antibody binding to IL1RAP could block signal transduction from IL-1 and IL-33 into cells and allow NK-cells to recognize tumor cells and subsequent killing by antibody-dependent cellular cytotoxicity (ADCC).

[0127] In some embodiments, the antigen is ASCT2. ASCT2 is also known as SLC1A5. ASCT2 is a ubiquitously expressed, broad-specificity, sodium-dependent neutral amino acid exchanger. ASCT2 is involved in glutamine transport. ASCT2 is overexpressed in different cancers and is closely related to poor prognosis. Downregulating ASCT2 has been shown to suppress intracellular glutamine levels and downstream glutamine metabolism, including glutathione production. Due to its high expression in many cancers, ASCT2 is a potential therapeutic target. These effects attenuated growth and proliferation, increased apoptosis and autophagy, and increased oxidative stress and mTORC1 pathway suppression in head and neck squamous cell carcinoma (HNSCC). Additionally, silencing ASCT2 improved the response to cetuximab in HNSCC.

[0128] In some embodiments, an antibody-drug conjugate (ADC) provided herein binds to TROP2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 289, 290, 291, 292, 293, and 294, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 295 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acidsequence of SEQ ID NO: 296. In some embodiments, the antibody of the antibody drug conjugate is sacituzumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences that are at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequences of SEQ ID NOs: 297, 298, 299, 300, 301, and 302, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 303 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 304. In some embodiments, the antibody of the antibody drug conjugate is datopotamab.

[0129] In some embodiments, an antibody-drug conjugate provided herein binds to MICA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 305, 306, 307, 308, 309, and 310, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 311 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312. In some embodiments, the antibody of the antibody drug conjugate is h1D5v11 hIgG1K. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 313, 314, 315, 316, 317, and 318, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 319 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 320. In some embodiments, the antibody of the antibody drug conjugate is MICA.36 hIgG1K G236A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 321, 322, 323, 324, 325, and 326, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 327and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 328. In some embodiments, the antibody of the antibody drug conjugate is h3F9 H1L3 hIgG1K. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 329, 330, 331, 332, 333, and 334, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 335 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 336. In some embodiments, the antibody of the antibody drug conjugate is CM33322 Ab28 hIgG1K.

[0130] In some embodiments, an antibody-drug conjugate provided herein binds to CD24. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1035, 1036, 1037, 1038, 1039, and 1040, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1041 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1042. In some embodiments, the antibody of the antibody drug conjugate is SWA11.

[0131] In some embodiments, an antibody-drug conjugate provided herein binds to ITGav (also known as CD51). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 337, 338, 339, 340, 341, and 342, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 343 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 344. In some embodiments, the antibody of the antibody drug conjugate is intetumumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 345, 346, 347, 348, 349, and 350, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising anamino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 351 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody of the antibody drug conjugate is abituzumab.

[0132] In some embodiments, an antibody-drug conjugate provided herein binds to gpA33. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 353, 354, 355, 356, 357, and 358, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 359 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 360.

[0133] In some embodiments, an antibody-drug conjugate provided herein binds to IL1Rap. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 361, 362, 363, 364, 365, and 366, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 367 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody of the antibody drug conjugate is nidanilimab.

[0134] In some embodiments, an antibody-drug conjugate provided herein binds to EpCAM. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 369, 370, 371, 372, 373, and 374, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 375 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 376. In some embodiments, the antibody of the antibody drug conjugate is adecatumumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 377, 378, 379, 380, 381, and 382, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 383 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 384. In some embodiments, the antibody of the antibody drug conjugate is Ep157305. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 385, 386, 387, 388, 389, and 390, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 391 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 392. In some embodiments, the antibody of the antibody drug conjugate is Ep3-171. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 393, 394, 395, 396, 397, and 398, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 399 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 400. In some embodiments, the antibody of the antibody drug conjugate is Ep3622w94. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 401, 402, 403, 404, 405, and 406, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 407 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 408. In some embodiments, the antibody of the antibody drug conjugate is EpING1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acidsequences of SEQ ID NOs: 409, 410, 411, 412, 413, and 414, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 415 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 416. In some embodiments, the antibody of the antibody drug conjugate is EpAb2-6.

[0135] In some embodiments, an antibody-drug conjugate provided herein binds to CD352. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 417, 418, 419, 420, 421, and 422, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 423 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the antibody of the antibody drug conjugate is h20F3.

[0136] In some embodiments, an antibody-drug conjugate provided herein binds to CS1 (also known as SLAMF7). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 425, 426, 427, 428, 429, and 430, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 431 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 432. In some embodiments, the antibody of the antibody drug conjugate is elotuzumab.

[0137] In some embodiments, an antibody-drug conjugate provided herein binds to CD38. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 433, 434, 435, 436, 437, and 438, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 439 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 440. In some embodiments, the antibody of the antibody drug conjugate is daratumumab.

[0138] In some embodiments, an antibody-drug conjugate provided herein binds to CD25. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 441, 442, 443, 444, 445, and 446, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 447 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 448. In some embodiments, the antibody of the antibody drug conjugate is daclizumab.

[0139] In some embodiments, an antibody-drug conjugate provided herein binds to ADAM9. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 449, 450, 451, 452, 453, and 454, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 455 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 456. In some embodiments, the antibody of the antibody drug conjugate is chMAbA9-A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 457, 458, 459, 460, 461, and 462, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 463 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 464. In some embodiments, the antibody of the antibody drug conjugate is hMAbA9-A. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1 comprising the amino acid sequences of SEQ ID NO: 449. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1 comprising the amino acid sequences of SEQ ID NO: 457. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L1 comprising the amino acid sequences of SEQ ID NO: 460.

[0140] In some embodiments, an antibody-drug conjugate provided herein binds to CD59. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 465, 466, 467, 468, 469, and 470, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 471 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 472. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1 comprising the amino acid sequence of SEQ ID NO: 465. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2 comprising the amino acid sequence of SEQ ID NO: 466.

[0141] In some embodiments, an antibody-drug conjugate provided herein binds to CD25. In some embodiments, the antibody of the antibody drug conjugate is Clone123.

[0142] In some embodiments, an antibody-drug conjugate provided herein binds to CD229. In some embodiments, the antibody of the antibody drug conjugate is h8A10.

[0143] In some embodiments, an antibody-drug conjugate provided herein binds to CD19. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 473, 474, 475, 476, 477, and 478, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 479 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 480. In some embodiments, the anti-CD19 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 481 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 482. In some embodiments, the antibody of the antibody drug conjugate is denintuzumab, which is also known as hBU12. See WO2009052431.

[0144] In some embodiments, an antibody-drug conjugate provided herein binds to CD70. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 279, 280, 281, 282, 283, and 284, respectively. In some embodiments, the antibody of the antibody drugconjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 285 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 286. In some embodiments, the antibody of the antibody drug conjugate is vorsetuzumab. In some cases, an antibody provided herein binds to CD70. In some such cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences comprising at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, or at least 95% sequence identity to the amino acid sequences of SEQ ID NOs: 279, 280, 281, 282, 283 and 284, respectively. In some cases, the antibody comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 sequences each comprising at most one mutation relative to the amino acid sequences of SEQ ID NOs: 279, 280, 281, 282, 283 and 284, respectively.

[0145] In some embodiments, an antibody-drug conjugate provided herein binds to B7-H3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 675, 676, 677, 678, 679, and 680, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 681 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 682. In some embodiments, the antibody of the antibody drug conjugate is mirzotamab.

[0146] In some cases, an antibody provided herein binds to B7-H4. In some cases, the antibody comprises a set of CDR sequences (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, respectively) of which each sequence comprises at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95%, or 100% sequence identity to amino acid sequences from a set of amino acid sequences selected from the group consisting of SEQ ID Nos: 57- 62, SEQ ID Nos: 71-76, SEQ ID Nos: 79-84, SEQ ID Nos: 87-92, SEQ ID Nos: 95-100, SEQ ID Nos:103-108, SEQ ID Nos: 111-116, SEQ ID Nos: 119-124, SEQ ID Nos: 127-132, SEQ ID Nos: 135-140, SEQ ID Nos: 143-148, SEQ ID Nos: 151-156, SEQ ID Nos: 159-164, SEQ ID Nos: 167- 172, SEQ ID Nos: 175-180, SEQ ID Nos: 183-188, SEQ ID Nos: 191-196, SEQ ID Nos: 199-204, SEQ ID Nos: 207-212, SEQ ID Nos: 215-220, and SEQ ID Nos: 223-228. In some cases, the antibody comprises a set of CDR sequences (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, respectively) each comprising at most one mutation relative to an amino acid sequence from a set of amino acid sequences selected from the group consisting of SEQ ID Nos: 1157-1162, SEQ ID Nos: 71-76, SEQ ID Nos: 79-84, SEQ ID Nos: 87-92, SEQ ID Nos: 95-100, SEQ ID Nos:103-108, SEQ IDNos: 111-116, SEQ ID Nos: 119-124, SEQ ID Nos: 127-132, SEQ ID Nos: 135-140, SEQ ID Nos: 143-148, SEQ ID Nos: 151-156, SEQ ID Nos: 159-164, SEQ ID Nos: 167-172, SEQ ID Nos: 175- 180, SEQ ID Nos: 183-188, SEQ ID Nos: 191-196, SEQ ID Nos: 199-204, SEQ ID Nos: 207-212, SEQ ID NOs: 215-220, and SEQ ID NOs: 223-228. In some cases, the anti-B7-H4 antibody comprises a heavy chain and a light chain comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequences of SEQ ID NO: 1165 and 67, SEQ ID NO: 66 and 67, SEQ ID NO: 68 and 67, SEQ ID NO: 69 and 67, SEQ ID NO: 68 and 70, SEQ ID NO: 69 and 70, SEQ ID NO: 231 and 232, SEQ ID NO: 233 and 234, SEQ ID NO: 235 and 236, SEQ ID NO: 237 and 238, SEQ ID NO: 239 and 240, SEQ ID NO: 241 and 242, SEQ ID NO: 243 and 244, SEQ ID NO: 245 and 246, SEQ ID NO: 247 and 248, SEQ ID NO: 249 and 250, SEQ ID NO: 251 and 252, SEQ ID NO: 253 and 254, SEQ ID NO: 255 and 256, SEQ ID NO: 257 and 258, SEQ ID NO: 259 and 260, SEQ ID NO: 261 and 262, SEQ ID NO: 263 and 264, SEQ ID NO: 265 and 266, SEQ ID NO: 267 and 268, or SEQ ID NO: 269 and 270, respectively. In some embodiments, the anti-B7-H4 antibody comprises a heavy chain variable region and a light chain variable region comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequences of SEQ ID NO: 1163 and 1164, SEQ ID NO: 77 and 78, SEQ ID NO: 85 and 86, SEQ ID NO: 93 and 94, SEQ ID NO: 101 and 102, SEQ ID NO: 109 and 110, SEQ ID NO: 117 and 118, SEQ ID NO: 125 and 126, SEQ ID NO: 133 and 134, SEQ ID NO: 141 and 142, SEQ ID NO: 149 and 150, SEQ ID NO: 157 and 158, SEQ ID NO: 165 and 166, SEQ ID NO: 173 and 174, SEQ ID NO: 181 and 182, SEQ ID NO: 189 and 190, SEQ ID NO: 197 and 198, SEQ ID NO: 205 and 206, SEQ ID NO: 213 and 214, SEQ ID NO: 221 and 222, or SEQ ID NO: 229 and 230, respectively.

[0147] In some embodiments, an antibody-drug conjugate provided herein binds to CD138. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 483, 484, 485, 486, 487, and 488, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 489 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 490. In some embodiments, the antibody of the antibody drug conjugate is indatuxumab.

[0148] In some embodiments, an antibody-drug conjugate provided herein binds to CD166. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 491, 492, 493, 494, 495, and 496, respectively. In some embodiments, the antibody of the antibody drugconjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 497 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 498. In some embodiments, the antibody of the antibody drug conjugate is praluzatamab.

[0149] In some embodiments, an antibody-drug conjugate provided herein binds to CD56. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 499, 500, 501, 502, 503, and 504, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 505 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 506. In some embodiments, the antibody of the antibody drug conjugate is lorvotuzumab.

[0150] In some embodiments, an antibody-drug conjugate provided herein binds to CD74. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 507, 508, 509, 510, 511, and 512, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 513 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 514. In some embodiments, the antibody of the antibody drug conjugate is milatuzumab.

[0151] In some embodiments, an antibody-drug conjugate provided herein binds to CEACAM5. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 515, 516, 517, 518, 519, and 520, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 521 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 522. In some embodiments, the antibody of the antibody drug conjugate is labetuzumab.

[0152] In some embodiments, an antibody-drug conjugate provided herein binds to CanAg. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 523, 524, 525, 526, 527, and 528, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 529 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 530. In some embodiments, the antibody of the antibody drug conjugate is cantuzumab.

[0153] In some embodiments, an antibody-drug conjugate provided herein binds to DLL-3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 531, 532, 533, 534, 535, and 536, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 537 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 538. In some embodiments, the antibody of the antibody drug conjugate is rovalpituzumab.

[0154] In some embodiments, an antibody-drug conjugate provided herein binds to DPEP-3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 539, 540, 541, 542, 543, and 544, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 545 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 546. In some embodiments, the antibody of the antibody drug conjugate is tamrintamab.

[0155] In some embodiments, an antibody-drug conjugate provided herein binds to EGFR. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively. In some embodiments, the antibody of the antibody drugconjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 553 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 554. In some embodiments, the antibody of the antibody drug conjugate is laprituximab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 555, 556, 557, 558, 559, and 560, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 561 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 562. In some embodiments, the antibody of the antibody drug conjugate is losatuxizumab. In some embodiments, the antibody of the antibody drug conjugate is serclutamab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 563, 564, 565, 566, 567, and 568, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 569 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 570. In some embodiments, the antibody of the antibody drug conjugate is cetuximab.

[0156] In some embodiments, an antibody-drug conjugate provided herein binds to FRa. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 571, 572, 573, 574, 575, and 576, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 577 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 578. In some embodiments, the antibody of the antibody drug conjugate is mirvetuximab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR- H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences ofSEQ ID NOs: 579, 580, 581, 582, 583, and 584, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 585 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 586. In some embodiments, the antibody of the antibody drug conjugate is farletuzumab.

[0157] In some embodiments, an antibody-drug conjugate provided herein binds to MUC-1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 587, 588, 589, 590, 591, and 592, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 593 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 594. In some embodiments, the antibody of the antibody drug conjugate is gatipotuzumab.

[0158] In some embodiments, an antibody-drug conjugate provided herein binds to mesothelin. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 595, 596, 597, 598, 599, and 600, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 601 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 602. In some embodiments, the antibody of the antibody drug conjugate is anetumab.

[0159] In some embodiments, an antibody-drug conjugate provided herein binds to ROR-1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 603, 604, 605, 606, 607, and 608, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 609 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 610. In some embodiments, the antibody of the antibody drug conjugate is zilovertamab.

[0160] In some embodiments, an antibody-drug conjugate provided herein binds to B7-H4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 95, 96, 97, 98, 99, and 100, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 101 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody of the antibody drug conjugate is 20502. See WO2019040780.

[0161] In some embodiments, an antibody-drug conjugate provided herein binds to B7-H3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 611, 612, 613, 614, 615, and 616, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 617 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618. In some embodiments, the antibody of the antibody drug conjugate is chAb-A (BRCA84D). In some embodiments, the antibody of the antibody drug conjugate is hAb-B. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 619, 620, 621, 622, 623, and 624, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 625 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 626. In some embodiments, the antibody of the antibody drug conjugate is hAb-C. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 627, 628, 629, 630, 631, and 632, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 633 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 634. In some embodiments, the antibody of the antibody drug conjugate is hAb-D. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 635, 636, 637, 638, 639, and 640, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 641 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 642. In some embodiments, the antibody of the antibody drug conjugate is chM30. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 643, 644, 645, 646, 647, and 648, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 649 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 650. In some embodiments, the antibody of the antibody drug conjugate is hM30-H1- L4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 651, 652, 653, 654, 655, and 656, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 657 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 658. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb18-v4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 659, 660, 661, 662, 663, and 664, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 665 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 666. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb3-v6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 667, 668, 669, 670, 671, and 672, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 673 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 674. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb3-v2.6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 675, 676, 677, 678, 679, and 680, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 681 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 682. In some embodiments, the antibody of the antibody drug conjugate is AbV_huAb13-v1-CR. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 683, 684, 685, 686, 687, and 688, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 689 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 690. In some embodiments, the antibody of the antibody drug conjugate is 8H9-6m. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 691 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical tothe amino acid sequence of SEQ ID NO: 692. In some embodiments, the antibody of the antibody drug conjugate is m8517. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 693, 694, 695, 696, 697, and 698, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 699 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 700. In some embodiments, the antibody of the antibody drug conjugate is TPP-5706. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 701 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 702. In some embodiments, the antibody of the antibody drug conjugate is TPP-6642. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 703 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 704. In some embodiments, the antibody of the antibody drug conjugate is TPP-6850. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2, comprising the amino acid sequence of SEQ ID NO: 612. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H3, comprising the amino acid sequence of SEQ ID NO: 613. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L1, comprising the amino acid sequence of SEQ ID NO: 614. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L2, comprising the amino acid sequence of SEQ ID NO: 615. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L3, comprising the amino acid sequence of SEQ ID NO: 616. In some embodiments, the antibody of the antibody drug conjugate is chAb-A (BRCA84D). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 619. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2, comprising the amino acid sequence of SEQ ID NO: 620. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H3, comprising the amino acid sequence of SEQ ID NO: 621. In some embodiments, the antibody of the antibody drugconjugate comprises CDR-L1, comprising the amino acid sequence of SEQ ID NO: 622. In some embodiments, the antibody of the antibody drug conjugate is hAb-B. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L3, comprising the amino acid sequence of SEQ ID NO: 624. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 627. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2, comprising the amino acid sequence of SEQ ID NO: 628. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H3, comprising the amino acid sequence of SEQ ID NO: 629. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L1, comprising the amino acid sequence of SEQ ID NO: 630. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L2, comprising the amino acid sequence of SEQ ID NO: 631. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L3, comprising the amino acid sequence of SEQ ID NO: 632. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 651. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 659. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H3, comprising the amino acid sequence of SEQ ID NO: 661. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 667. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, comprising the amino acid sequence of SEQ ID NO: 675. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2, comprising the amino acid sequence of SEQ ID NO: 684. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L3, comprising the amino acid sequence of SEQ ID NO: 688.

[0162] In some embodiments, an antibody-drug conjugate provided herein binds to CDCP1. In some embodiments, the antibody of the antibody drug conjugate is 10D7.

[0163] In some embodiments, an antibody-drug conjugate provided herein binds to HER3. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 705 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 706. In some embodiments, the antibody of the antibody drug conjugate is patritumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 707 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%identical to the amino acid sequence of SEQ ID NO: 708. In some embodiments, the antibody of the antibody drug conjugate is seribantumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 709 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 710. In some embodiments, the antibody of the antibody drug conjugate is elgemtumab. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 711 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712. In some embodiments, the antibody of the antibody drug conjugate is lumretuzumab.

[0164] In some embodiments, an antibody-drug conjugate provided herein binds to RON. In some embodiments, the antibody of the antibody drug conjugate is Zt / g4.

[0165] In some embodiments, an antibody-drug conjugate provided herein binds to claudin-2.

[0166] In some embodiments, an antibody-drug conjugate provided herein binds to HLA-G.

[0167] In some embodiments, an antibody-drug conjugate provided herein binds to PTK7. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 713, 714, 715, 716, 717, and 718, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 719 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 720. In some embodiments, the antibody of the antibody drug conjugate is PTK7 mab 1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 721, 722, 723, 724, 725, and 726, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 727 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 728. In some embodiments, the antibody of the antibody drug conjugate isPTK7 mab 2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 729, 730, 731, 732, 733, and 734, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 735 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 736. In some embodiments, the antibody of the antibody drug conjugate is PTK7 mab 3.

[0168] In some embodiments, an antibody-drug conjugate provided herein binds to LIV1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 737, 738, 739, 740, 741, and 742, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 743 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 744. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 745 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 746. In some embodiments, the antibody of the antibody drug conjugate is ladiratuzumab, which is also known as hLIV22 and hglg. See WO2012078668.

[0169] In some embodiments, an antibody-drug conjugate provided herein binds to integrin avb6 (or integrin beta 6 / ITGB6). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 43, 44, 45, 46, 47, and 48, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the antibody of the antibody drugconjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51 or SEQ ID NO: 52 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 54 or SEQ ID NO: 55 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 56. In some embodiments, the antibody of the antibody drug conjugate is h2A2. See PCT / US20 / 63390. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR- L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 747, 748, 749, 750, 751, and 752, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 753 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 754. In some embodiments, the antibody of the antibody drug conjugate is h15H3. See WO 2013 / 123152.

[0170] In some cases, an antibody provided herein binds to integrin avB6 (or integrin beta 6 / ITGB6). In some such cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR- L2, and CDR-L3 sequences comprising at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, or at least 95% sequence identity to the amino acid sequences of SEQ ID NOs: 1143, 1144, 1145, 1146, 1147, and 1148, respectively. In some cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences each comprising at most one mutation relative to the amino acid sequences of SEQ ID NOs: 1143, 1144, 1145, 1146, 1147, and 1148, respectively. In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1149 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1150. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of either SEQ ID NO: 1151 or 1152 and a lightchain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1153. In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of either SEQ ID NO: 1154 or 1155 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1156.

[0171] In some embodiments, an antibody-drug conjugate provided herein binds to CD48. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 755, 756, 757, 758, 759, and 760, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 761 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 762. In some embodiments, the antibody of the antibody drug conjugate is hMEM102. See WO2016149535.

[0172] In some embodiments, an antibody-drug conjugate provided herein binds to PD-L1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 271, 272, 273, 274, 275, and 276, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 277 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody of the antibody drug conjugate is SG-559-01 mAb or SG-559-01 LALA mAb. See PCT / US2020 / 054037.

[0173] In some cases, an anti-PDL1 antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to the amino acid sequences of SEQ ID NOs: 271, 272, 273, 274, 275, and 276, respectively. In some cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 each comprising at most one mutation relative to the amino acid sequences of SEQ ID NOs: 271, 272, 273, 274, 275, and 276, respectively.

[0174] In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 277 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 278.

[0175] In some embodiments, an antibody provided herein binds to EphA2. In some embodiments, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the amino acid sequences of SEQ ID NOs: 1112, 1113, 1114, 1115, 1116, and 1117, respectively.

[0176] In some embodiments, the anti-EphA2 antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1119. In some embodiments, the anti- EphA2 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1120 or SEQ ID NO: 1121 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1122. In some embodiments, the anti-EphA2 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1123 or SEQ ID NO: 1124 and a light chain comprising the amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1125. In some embodiments, the anti-EphA2 antibody comprises a heavy chain that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1126 or SEQ ID NO: 1127 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1128. In some embodiments, the antibody is h1C1 or 1C1.

[0177] In some embodiments, the anti-EphA2 antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence ofSEQ ID NO: 1118 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1119.

[0178] In some embodiments, an antibody-drug conjugate provided herein binds to IGF-1R. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 763, 764, 765, 766, 767, and 768, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 769 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 770. In some embodiments, the antibody of the antibody drug conjugate is cixutumumab.

[0179] In some embodiments, an antibody-drug conjugate provided herein binds to claudin-18.2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 771, 772, 773, 774, 775, and 776, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 777 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 778. In some embodiments, the antibody of the antibody drug conjugate is zolbetuximab (175D10). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 779, 780, 781, 782, 783, and 784, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 785 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 786. In some embodiments, the antibody of the antibody drug conjugate is 163E12.

[0180] In some embodiments, an antibody-drug conjugate provided herein binds to Nectin-4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 787, 788,789, 790, 791, and 792, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 793 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 794. In some embodiments, the antibody of the antibody drug conjugate is enfortumab. See WO 2012047724.

[0181] In some embodiments, an antibody-drug conjugate provided herein binds to SLTRK6. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 795, 796, 797, 798, 799, and 800, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 801 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 802. In some embodiments, the antibody of the antibody drug conjugate is sirtratumab.

[0182] In some embodiments, an antibody-drug conjugate provided herein binds to CD228. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1129, 1130, 1131, 1132, 1133, and 1134, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1135 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1136. In some embodiments, the antibody of the antibody drug conjugate is hL49. See WO 2020 / 163225.

[0183] In some cases, an antibody provided herein binds to CD228. In some such cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences comprising at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, or at least 95% sequence identity to the amino acid sequences of SEQ ID NOs: 1129, 1130, 1131, 1132, 1133, and 1134, respectively. In some cases, the antibody comprises CDR-H1, CDR-H2, CDR-H3, CDR- L1, CDR-L2, and CDR-L3 sequences each comprising at most one mutation relative to the amino acid sequences of SEQ ID NOs: 1129, 1130, 1131, 1132, 1133, and 1134, respectively. In some embodiments, the anti-CD228 antibody comprises a heavy chain variable region comprising an aminoacid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1135 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1136. In some embodiments, the anti-CD228 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of either of SEQ ID NO: 1137 or 1138 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1139. In some embodiments, the anti-CD228 antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of either of SEQ ID NO: 1140 or 41 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1142.

[0184] In some embodiments, an antibody-drug conjugate provided herein binds to CD142 (tissue factor; TF). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 803, 804, 805, 806, 807, and 808, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 809 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 810. In some embodiments, the antibody of the antibody drug conjugate is tisotumab. See WO 2010 / 066803.

[0185] In some embodiments, an antibody-drug conjugate provided herein binds to STn. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 811, 812, 813, 814, 815, and 816, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 817 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818. In some embodiments, the antibody of the antibody drug conjugate is h2G12.

[0186] In some embodiments, an antibody-drug conjugate provided herein binds to CD20. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 819, 820, 821, 822, 823, and 824, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 825 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 826. In some embodiments, the antibody of the antibody drug conjugate is rituximab.

[0187] In some embodiments, an antibody-drug conjugate provided herein binds to HER2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 827, 828, 829, 830, 831, and 832, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 833 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 834. In some embodiments, the antibody of the antibody drug conjugate is trastuzumab. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1048, 1049, 1050, 1051, 1052, and 1053, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1054 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1055. In some embodiments, the antibody of the antibody drug conjugate is disitamab / RC-48.

[0188] In some embodiments, an antibody-drug conjugate provided herein binds to FLT3.

[0189] In some embodiments, an antibody-drug conjugate provided herein binds to CD46.

[0190] In some embodiments, an antibody-drug conjugate provided herein binds to GloboH.

[0191] In some embodiments, an antibody-drug conjugate provided herein binds to AG7.

[0192] In some embodiments, an antibody-drug conjugate provided herein binds to mesothelin.

[0193] In some embodiments, an antibody-drug conjugate provided herein binds to FCRH5.

[0194] In some embodiments, an antibody-drug conjugate provided herein binds to ETBR.

[0195] In some embodiments, an antibody-drug conjugate provided herein binds to Tim-1.

[0196] In some embodiments, an antibody-drug conjugate provided herein binds to SLC44A4.

[0197] In some embodiments, an antibody-drug conjugate provided herein binds to ENPP3.

[0198] In some embodiments, an antibody-drug conjugate provided herein binds to CD37.

[0199] In some embodiments, an antibody-drug conjugate provided herein binds to CA9.

[0200] In some embodiments, an antibody-drug conjugate provided herein binds to Notch3.

[0201] In some embodiments, an antibody-drug conjugate provided herein binds to EphA2.

[0202] In some embodiments, an antibody-drug conjugate provided herein binds to TRFC.

[0203] In some embodiments, an antibody-drug conjugate provided herein binds to PSMA.

[0204] In some embodiments, an antibody-drug conjugate provided herein binds to LRRC15.

[0205] In some embodiments, an antibody-drug conjugate provided herein binds to 5T4.

[0206] In some embodiments, an antibody-drug conjugate provided herein binds to CD79b. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 835, 836, 837, 838, 839, and 840, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 841 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 842. In some embodiments, the antibody of the antibody drug conjugate is polatuzumab.

[0207] In some embodiments, an antibody-drug conjugate provided herein binds to NaPi2B. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 843, 844, 845, 846, 847, and 848, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 849 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 850. In some embodiments, the antibody of the antibody drug conjugate is lifastuzumab.

[0208] In some embodiments, an antibody-drug conjugate provided herein binds to Muc16. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 851, 852, 853, 854, 855, and 856, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identical to the amino acid sequence of SEQ ID NO: 857 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 858. In some embodiments, the antibody of the antibody drug conjugate is sofituzumab.

[0209] In some embodiments, an antibody-drug conjugate provided herein binds to STEAP1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 859, 860, 861, 862, 863, and 864, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 865 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 866. In some embodiments, the antibody of the antibody drug conjugate is vandortuzumab.

[0210] In some embodiments, an antibody-drug conjugate provided herein binds to BCMA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 867, 868, 869, 870, 871, and 872, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 873 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 874. In some embodiments, the antibody of the antibody drug conjugate is belantamab.

[0211] In some embodiments, an antibody-drug conjugate provided herein binds to c-Met. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 875, 876, 877, 878, 879, and 880, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 881 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 882. In some embodiments, the antibody of the antibody drug conjugate is telisotuzumab.

[0212] In some embodiments, an antibody-drug conjugate provided herein binds to EGFR. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 883, 884, 885, 886, 887, and 888, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 889 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 890. In some embodiments, the antibody of the antibody drug conjugate is depatuxizumab.

[0213] In some embodiments, an antibody-drug conjugate provided herein binds to SLAMF7. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 891, 892, 893, 894, 895, and 896, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 897 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 898. In some embodiments, the antibody of the antibody drug conjugate is azintuxizumab.

[0214] In some embodiments, an antibody-drug conjugate provided herein binds to C4.4a (also known as LYPD3). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 899, 900, 901, 902, 903, and 904, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 905 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 906. In some embodiments, the antibody of the antibody drug conjugate is lupartumab.

[0215] In some embodiments, an antibody-drug conjugate provided herein binds to GCC. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 907, 908, 909, 910, 911, and 912, respectively. In some embodiments, the antibody of the antibody drugconjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 913 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 914. In some embodiments, the antibody of the antibody drug conjugate is indusatumab.

[0216] In some embodiments, an antibody-drug conjugate provided herein binds to Axl. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 915, 916, 917, 918, 919, and 920, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 921 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 922. In some embodiments, the antibody of the antibody drug conjugate is enapotamab.

[0217] In some embodiments, an antibody-drug conjugate provided herein binds to gpNMB. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 923, 924, 925, 926, 927, and 928, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 929 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 930. In some embodiments, the anti-gpNMB antibody comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 931 and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 932. In some embodiments, the antibody of the antibody drug conjugate is glembatumumab.

[0218] In some embodiments, an antibody-drug conjugate provided herein binds to Prolactin receptor (PRLR). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 933, 934, 935, 936, 937, and 938, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequencethat is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 939 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 940. In some embodiments, the antibody of the antibody drug conjugate is rolinsatamab.

[0219] In some embodiments, an antibody-drug conjugate provided herein binds to FGFR2. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 941, 942, 943, 944, 945, and 946, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 947 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 948. In some embodiments, the antibody of the antibody drug conjugate is aprutumab.

[0220] In some embodiments, an antibody-drug conjugate provided herein binds to CDCP1. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 949, 950, 951, 952, 953, and 954, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 955 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 956. In some embodiments, the antibody of the antibody drug conjugate is Humanized CUB4 #135 HC4-H. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 957, 958, 959, 960, 961, and 962, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 963 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 964. In some embodiments, the antibody of the antibody drug conjugate is CUB4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequencesof SEQ ID NOs: 965, 966, 967, 968, 969, 970, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 971 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 972. In some embodiments, the antibody of the antibody drug conjugate is CP13E10-WT. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 973, 974, 975, 976, 977, and 978, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 979 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 980. In some embodiments, the antibody of the antibody drug conjugate is CP13E10-54HCv13-89LCv1. In some embodiments, an antibody-drug conjugate provided herein binds to CDCP1. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 955 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 956. In some embodiments, the antibody of the antibody drug conjugate is Humanized CUB4 #135 HC4-H. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 963 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 964. In some embodiments, the antibody of the antibody drug conjugate is CUB4. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 965, 966, 967, 968, 969, 970, respectively.

[0221] In some embodiments, an antibody-drug conjugate provided herein binds to ASCT2. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 981 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 982. In some embodiments, the antibody of the antibody drug conjugate is KM8094a. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 983 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 984. In some embodiments, the antibody of the antibody drug conjugate is KM8094b. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR- H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 985, 986, 987, 988, 989, and 990, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 991 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 992. In some embodiments, the antibody of the antibody drug conjugate is KM4018.

[0222] In some embodiments, an antibody-drug conjugate provided herein binds to CD123. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 993, 994, 995, 996, 997, and 998, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 999 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1000. In some embodiments, the antibody of the antibody drug conjugate is h7G3. See WO 2016201065.

[0223] In some embodiments, an antibody-drug conjugate provided herein binds to GPC3. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1001, 1002, 1003, 1004, 1005, and 1006, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identical to the amino acid sequence of SEQ ID NO: 1007 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1008. In some embodiments, the antibody of the antibody drug conjugate is hGPC3-1. See WO 2019161174. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H2, comprising the amino acid sequence of SEQ ID NO: 1002. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-L1, comprising the amino acid sequence of SEQ ID NO: 1004.

[0224] In some embodiments, an antibody-drug conjugate provided herein binds to TIGIT. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1009, 1010, 1011, 1012, 1013, and 1014, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1015 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1016. In some embodiments, the antibody of the antibody drug conjugate is Clone 13 (also known as ADI-23674 or mAb13). See WO 2020041541. In some embodiments, an antibody- drug conjugate provided herein binds to TIGIT. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1009, 1010, 1011, 1012, 1013, and 1014, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H3, comprising the amino acid sequence of SEQ ID NO: 1011.

[0225] In some embodiments, an antibody-drug conjugate provided herein binds to STN. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 811, 812, 813, 814, 815, and 816, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 817 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818. In some embodiments, the antibody of the antibody drug conjugate is 2G12-2B2. See WO 2017083582.

[0226] In some embodiments, an antibody-drug conjugate provided herein binds to CD33. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3,CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1017, 1018, 1019, 1020, 1021, and 1022, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1023 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1024. In some embodiments, the antibody of the antibody drug conjugate is h2H12. See WO2013173496.

[0227] In some embodiments, an antibody-drug conjugate provided herein binds to NTBA (also known as CD352). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 417, 418, 419, 420, 421, and 422, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 423 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the antibody of the antibody drug conjugate is h20F3 HDLD. See WO 2017004330.

[0228] In some embodiments, an antibody-drug conjugate provided herein binds to BCMA. In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 1025, 1026, 1027, 1028, 1029, and 1030, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1031 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1032. In some embodiments, the antibody of the antibody drug conjugate is SEA- BCMA (also known as hSG16.17). See WO 2017 / 143069.

[0229] In some embodiments, an antibody-drug conjugate provided herein binds to Tissue Factor (also known as TF). In some embodiments, the antibody of the antibody drug conjugate comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences of SEQ ID NOs: 803, 804, 805, 806, 807, and 808, respectively. In some embodiments, the antibody of the antibody drug conjugate comprises a heavy chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 809 and a light chain variable region comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 810. In some embodiments, the antibody of the antibody drug conjugate is tisotumab. See WO 2010 / 066803 and US 9,150,658.

[0230] Antibody sequences useful in the ADCs of the present disclosure are provided in Table 1. Table 1. Antibody sequences SEQ ID Description Sequence NO 1 Ab1 heavy QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ chain KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS variable region 2 Ab1 light EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG chain SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK variable region 3 Ab1 heavy TYAIS chain CDR1 4 Ab1 heavy GIIPIFGKAHYAQKFQG chain CDR2 5 Ab1 heavy KFHFVSGSPFGMDV chain CDR3 6 Ab1 light RASQSVSSYLA chain CDR1 7 Ab1 light DASNRAT chain CDR2 8 Ab1 light QQRSNWPT chain CDR3 9 SG-559-01 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ LALA KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA hIgG1 heavy STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS chain LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK 10 SG-559-01 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG kappa light SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA chain SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC 11 SG-559-01 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ heavy chain KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS variable region 12 SG-559-01 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG light chain SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK variable region 13 SG-559-01 TAAIS heavy chain CDR1SG-559-01 GIIPIFGKAHYAQKFQG heavy chain CDR2 SG-559-01 KFHFVSGSPFGMDV heavy chain CDR3 SG-559-01 RASQSVSSYLA light chain CDR1 SG-559-01 DASNRAT light chain CDR2 SG-559-01 QQRSNWPT light chain CDR3 SG-559-02 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ LALA KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA hIgG1 heavy STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS chain LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-02 EIVLTQSPATLSLSPGERATLSCRASQSVSSALAWYQQKPGQAPRLLIYDASNRATGIPARFSG kappa light SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA chain SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC SG-559-02 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ heavy chain KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS variable region SG-559-02 EIVLTQSPATLSLSPGERATLSCRASQSVSSALAWYQQKPGQAPRLLIYDASNRATGIPARFSG light chain SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK variable region SG-559-02 TYAIS heavy chain CDR1 SG-559-02 GIIPIFGKAHYAQKFQG heavy chain CDR2 SG-559-02 KFHFVSGSPFGMDV heavy chain CDR3 SG-559-02 RASQSVSSALA light chain CDR1 SG-559-02 DASNRAT light chain CDR2 SG-559-02 QQRSNWPT light chain CDR3 SG-559-03 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ LALA KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA hIgG1 heavy STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS chain LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-03 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG kappa light SGSGTDFTLTISSLEPEDFAVYYCQQRSNLPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA chain SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGECSG-559-03 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ heavy chain KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS variable region SG-559-03 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG light chain SGSGTDFTLTISSLEPEDFAVYYCQQRSNLPTFGQGTKVEIK variable region SG-559-03 TYAIS heavy chain CDR1 SG-559-03 GIIPIFGKAHYAQKFQG heavy chain CDR2 SG-559-03 KFHFVSGSPFGMDV heavy chain CDR3 SG-559-03 RASQSVSSYLA light chain CDR1 SG-559-03 DASNRAT light chain CDR2 SG-559-03 QQRSNLPT light chain CDR3 SG-559-04 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ LALA KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSGFGMDVWGQGTTVTVSSA hIgG1 heavy STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS chain LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-04 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG kappa light SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA chain SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC SG-559-04 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ heavy chain KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSGFGMDVWGQGTTVTVSS variable region SG-559-04 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG light chain SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK variable region SG-559-04 TYAIS heavy chain CDR1 SG-559-04 GIIPIFGKAHYAQKFQG heavy chain CDR2 SG-559-04 KFHFVSGSGFGMDV heavy chain CDR3 SG-559-04 RASQSVSSYLA light chain CDR1 SG-559-04 DASNRAT light chain CDR2 SG-559-04 QQRSNWPT light chain CDR3SG-559-05 GIIPIAGKAHYAQKFQG heavy chain CDR2 SG-559-06 GIIPIFGAAHYAQKFQG heavy chain CDR2 SG-559-07 GIIPIFGRAHYAQKFQG heavy chain CDR2 SG-559-08 GIIPIFGKAAYAQKFQG heavy chain CDR2 SG-559-09 GIIPIFGKAFYAQKFQG heavy chain CDR2 SG-559-10 KFHFVSGAPFGMDV heavy chain CDR3 SG-559-11 KFHFVSGSPAGMDV heavy chain CDR3 SG-559-12 QQASNWPT light chain CDR3 SG-559-13 QQKSNWPT light chain CDR3 SG-559-14 QQRSAWPT light chain CDR3 SG-559-15 QQRSQWPT light chain CDR3 SG-559-16 QQRSNAPT light chain CDR3 SG-559-17 QQRSNFPT light chain CDR3 SG-559-01 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ hIgG1 heavy KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA chain STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-02 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ hIgG1 heavy KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA chain STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-03 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ hIgG1 heavy KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSSA chain STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK SG-559-04 QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ hIgG1 heavy KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSGFGMDVWGQGTTVTVSSA chain STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK B7H41001 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC v2 LRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPG B7H41001 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H41001 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS LALAKA LRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSSASTKGPS HC VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK B7H41001 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS LALAKA LRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSSASTKGPS HC v2 VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPG B7H41001 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG LALAKA SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT LC ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15461 GSISSSSYYWG CDR-H1 B7H4-15461 NIYYSGSTYYNPSLKS CDR-H2 B7H4-15461 AREGSYPNWFDP CDR-H3 B7H4-15461 RASQSVSSNLA CDR-L1 B7H4-15461 GASTRAT CDR-L2 B7H4-15461 QQYHSFPFT CDR-L3 B7H4-15461 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS VH LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSS B7H4-15461 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG VL SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK B7H4-20500 GSIKSGSHYWG CDR-H1 B7H4-20500 NIYYSGSTYYNPSLRS CDR-H2 B7H4-20500 AREGSYPNWFDP CDR-H3 B7H4-20500 RASQSVSSNLA CDR-L1 B7H4-20500 GASTRAT CDR-L2 B7H4-20500 QQYHSFPFT CDR-L3B7H4-20500 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS VH LRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSS B7H4-20500 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG VL SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK B7H4-20501 GSIKSGSHYWG CDR-H1 B7H4-20501 NIYYSGSTYYNPSLKS CDR-H2 B7H4-20501 AREGSYPNWLDP CDR-H3 B7H4-20501 RASQSVSSNLA CDR-L1 B7H4-20501 GASTRAT CDR-L2 B7H4-20501 QQYHSFPFT CDR-L3 B7H4-20501 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS VH LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWLDPWGQGTLVTVSS B7H4-20501 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG VL SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK B7H4- GSIKSGSYYWG 20502.1 CDR-H1 B7H4- NIYYSGSTYYNPSLKS 20502.1 CDR-H2 B7H4- AREGSYPNQFDP 20502.1 CDR-H3 B7H4- RASQSVSSNLA 20502.1 CDR-L1 B7H4- GASTRAT 20502.1 CDR-L2 B7H4- QQYHSFPFT 20502.1 CDR-L3 B7H4- QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS 20502.1 VH LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGILVTVSS B7H4- EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG 20502.1 VL SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK B7H4-22208 GSIKSGSHYWG CDR-H1 B7H4-22208 NIYYSGSTYYNPSLKS CDR-H2 B7H4-22208 AREGSYPNWFDP CDR-H3 B7H4-22208 RASQSVSTNLA CDR-L1 B7H4-22208 DASARVT CDR-L2 B7H4-22208 QQYHSFPFT CDR-L3 B7H4-22208 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS VH LKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSS B7H4-22208 EIVMTQSPATLSVSPGERATLSCRASQSVSTNLAWYQQKPGQAPRLLIYDASARVTGIPARFSG VL SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK B7H4-15462 GSISSSSYYWG CDR-H1 B7H4-15462 NIYYSGSTYYNPSLKS CDR-H2 B7H4-15462 AREGSYTTVLNV CDR-H3B7H4-15462 RASQSVSSSYLA CDR-L1 B7H4-15462 GASSRAT CDR-L2 B7H4-15462 QQAASYPLT CDR-L3 B7H4-15462 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS VH LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYTTVLNVWGQGTMVTVSS B7H4-15462 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG VL SGSGTDFTLTISRLEPEDFAVYYCQQAASYPLTFGGGTKVEIK B7H4-22213 GSIGRGSYYWG CDR-H1 B7H4-22213 NIYYSGSTYYNPSLKS CDR-H2 B7H4-22213 AREGSYTTVLNV CDR-H3 B7H4-22213 RASQSVASSHLA CDR-L1 B7H4-22213 DAVSRAT CDR-L2 B7H4-22213 QQAASYPLT CDR-L3 B7H4-22213 QLQLQESGPGLVKPSETLSLTCTVSGGSIGRGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNP VH SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYTTVLNVWGQGTMVTVSS B7H4-22213 EIVLTQSPGTLSLSPGERATLSCRASQSVASSHLAWYQQKPGQAPRLLIYDAVSRATGIPDRFS VL GSGSGTDFTLTISRLEPEDFAVYYCQQAASYPLTFGGGTKVEIK B7H4-15465 GSISSGGYYWS CDR-H1 B7H4-15465 NIYYSGSTYYNPSLKS CDR-H2 B7H4-15465 ARESSTISADFDL CDR-H3 B7H4-15465 RASQGISRWLA CDR-L1 B7H4-15465 AASSLQS CDR-L2 B7H4-15465 QQAHTFPYT CDR-L3 B7H4-15465 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP VH SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESSTISADFDLWGRGTLVTVSS B7H4-15465 DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS VL GSGSGTDFTLTISSLQPEDFATYYCQQAHTFPYTFGGGTKVEIK B7H4-20506 GSISHGGYYWS CDR-H1 B7H4-20506 NIYYSGSTYYNPSLKS CDR-H2 B7H4-20506 ARESSTISADFDL CDR-H3 B7H4-20506 RASQGISRWLA CDR-L1 B7H4-20506 AASSLQS CDR-L2 B7H4-20506 QQAHTFPYT CDR-L3 B7H4-20506 QLQLQESGPGLVKPSETLSLTCTASGGSISHGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP VH SLKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARESSTISADFDLWGRGTLVTVSS B7H4-20506 DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS VL GSGSGTDFTLTISSLQPEDFATYYCQQAHTFPYTFGGGTKVEIK B7H4-15483 GSISSGGYYWS CDR-H1 B7H4-15483 NIYYSGSTYYNPSLKS CDR-H2 B7H4-15483 ARGLSTIDEAFDP CDR-H3B7H4-15483 RASQSISSWLA CDR-L1 B7H4-15483 KASSLES CDR-L2 B7H4-15483 QQDNSYPYT CDR-L3 B7H4-15483 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP VH SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSS B7H4-15483 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIK B7H4-20513 GSISDGSYYWS CDR-H1 B7H4-20513 NIYYSGSTYYNPSLRS CDR-H2 B7H4-20513 ARGLSTIDEAFDP CDR-H3 B7H4-20513 RASQSISSWLA CDR-L1 B7H4-20513 KASSLES CDR-L2 B7H4-20513 QQDNSYPYT CDR-L3 B7H4-20513 QLQLQESGPGLVKPSETLSLTCTVSGGSISDGSYYWSWIRQHPGKGLEWIGNIYYSGSTYYNPS VH LRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSS B7H4-20513 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIK B7H4-22216 GSISDGSYYWS CDR-H1 B7H4-22216 NIYYSGSTYYNPSLRS CDR-H2 B7H4-22216 ARGLSTIDEAFDP CDR-H3 B7H4-22216 RASKSISSWLA CDR-L1 B7H4-22216 EASSLHS CDR-L2 B7H4-22216 QQDNSYPYT CDR-L3 B7H4-22216 QVQLQESGPGLVKPSQTLSLTCTVSGGSISDGSYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP VH SLRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSS B7H4-22216 DIQMTQSPSTLSASVGDRVTITCRASKSISSWLAWYQQKPGKAPKLLIYEASSLHSGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIK B7H4-15489 GSISSYYWS CDR-H1 B7H4-15489 YIYSSGSTNYNPSLKS CDR-H2 B7H4-15489 ARGSGQYAAPDYGMD CDR-H3 B7H4-15489 RASQSISSWLA CDR-L1 B7H4-15489 KASSLES CDR-L2 B7H4-15489 QQDNSFPFT CDR-L3 B7H4-15489 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYSSGSTNYNPSLK VH SRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSGQYAAPDYGMDVWGQGTTVTVSS B7H4-15489 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQDNSFPFTFGGGTKVEIK B7H4-20516 GSIISYYWG CDR-H1 B7H4-20516 YIYSSGSTSYNPSLKS CDR-H2 B7H4-20516 ARGSGLYAAPDYGLDV CDR-H3B7H4-20516 RASQSISSWLA CDR-L1 B7H4-20516 KASSLES CDR-L2 B7H4-20516 QQDNSFPFT CDR-L3 B7H4-20516 QVQLQESGPGLVKPSETLSLTCTVSGGSIISYYWGWIRQPPGKGLEWIGYIYSSGSTSYNPSLKS VH RVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSGLYAAPDYGLDVWGQGTTVTVSS B7H4-20516 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQDNSFPFTFGGGTKVEIK B7H4-15472 FTFSSYAMS CDR-H1 B7H4-15472 TISGSGGSTYYADSVKG CDR-H2 B7H4-15472 ARGAGHYDLVGRY CDR-H3 B7H4-15472 RASQSISSYLN CDR-L1 B7H4-15472 AASSLQS CDR-L2 B7H4-15472 QQLYSLPPT CDR-L3 B7H4-15472 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISGSGGSTYYAD VH SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGAGHYDLVGRYWGQGTLVTVSS B7H4-15472 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG VL SGSGTDFTLTISSLQPEDFATYYCQQLYSLPPTFGGGTKVEIK B7H4-15503 FTFSSYAMS CDR-H1 B7H4-15503 AISGSGGSTYYADSVKG CDR-H2 B7H4-15503 ARVGFRALNY CDR-H3 B7H4-15503 RASQDISSWLA CDR-L1 B7H4-15503 AASSLQS CDR-L2 B7H4-15503 QQATSYPPWT CDR-L3 B7H4-15503 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYAD VH SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGFRALNYWGQGTTVTVSS B7H4-15503 DIQLTQSPSSVSASVGDRVTITCRASQDISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSG VL SGSGTDFTLTISSLQPEDFATYYCQQATSYPPWTFGGGTKVEIK B7H4-15495 GTFSSYAIS CDR-H1 B7H4-15495 GIIPIFGTASYAQKFQG CDR-H2 B7H4-15495 ARQQYDGRRYFGL CDR-H3 B7H4-15495 RASQSVSSNLA CDR-L1 B7H4-15495 SASTRAT CDR-L2 B7H4-15495 QQVNVWPPT CDR-L3 B7H4-15495 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTASYAQ VH KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARQQYDGRRYFGLWGRGTLVTVSS B7H4-15495 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSG VL SGSGTEFTLTISSLQSEDFAVYYCQQVNVWPPTFGGGTKVEIK B7H4-15478 GTFSSYAIS CDR-H1 B7H4-15478 GIIPIFGTANYAQKFQG CDR-H2 B7H4-15478 ARGGPWFDP CDR-H3B7H4-15478 RASQSISSWLA CDR-L1 B7H4-15478 KASSLES CDR-L2 B7H4-15478 QQYNSYPPFT CDR-L3 B7H4-15478 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ VH KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGPWFDPWGQGTLVTVSS B7H4-15478 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQYNSYPPFTFGGGTKVEIK B7H4-15441 FTFSSYAMS CDR-H1 B7H4-15441 AISGSGGSTSYADSVKG CDR-H2 B7H4-15441 AKPSLATMLAFDI CDR-H3 B7H4-15441 RASQSISSWLA CDR-L1 B7H4-15441 DASSLES CDR-L2 B7H4-15441 QQSKSYPRT CDR-L3 B7H4-15441 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTSYAD VH SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSLATMLAFDIWGQGTMVTVSS B7H4-15441 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG VL SGSGTEFTLTISSLQPDDFATYYCQQSKSYPRTFGGGTKVEIK B7H4-20496 GSISSSVYYWS CDR-H1 B7H4-20496 SILVSGSTYYNPSLKS CDR-H2 B7H4-20496 ARAVSFLDV CDR-H3 B7H4-20496 RASQSISSYLN CDR-L1 B7H4-20496 GASSLQS CDR-L2 B7H4-20496 QQSYDPPWT CDR-L3 B7H4-20496 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSVYYWSWIRQPPGKGLEWIGSILVSGSTYYNPSL VH KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAVSFLDVWGQGTMVIVSS B7H4-20496 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSG VL SGSGTDFTLTISSLQPEDFATYYCQQSYDPPWTFGGGTKVEIK B7H4-15461 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-15461 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-20500 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC LRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-20500 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGECB7H4-20501 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWLDPWGQGTLVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-20501 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4- QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS 20502.1 HC LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGILVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK B7H4- EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSG 20502.1 LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-22208 QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSHYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC LKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNWFDPWGQGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-22208 EIVMTQSPATLSVSPGERATLSCRASQSVSTNLAWYQQKPGQAPRLLIYDASARVTGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15462 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPS HC LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYTTVLNVWGQGTMVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-15462 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG LC SGSGTDFTLTISRLEPEDFAVYYCQQAASYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-22213 QLQLQESGPGLVKPSETLSLTCTVSGGSIGRGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNP HC SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYTTVLNVWGQGTMVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-22213 EIVLTQSPGTLSLSPGERATLSCRASQSVASSHLAWYQQKPGQAPRLLIYDAVSRATGIPDRFS LC GSGSGTDFTLTISRLEPEDFAVYYCQQAASYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15465 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP HC SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESSTISADFDLWGRGTLVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-15465 DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS LC GSGSGTDFTLTISSLQPEDFATYYCQQAHTFPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-20506 QLQLQESGPGLVKPSETLSLTCTASGGSISHGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP HC SLKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARESSTISADFDLWGRGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-20506 DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS LC GSGSGTDFTLTISSLQPEDFATYYCQQAHTFPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15483 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP HC SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-15483 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-20513 QLQLQESGPGLVKPSETLSLTCTVSGGSISDGSYYWSWIRQHPGKGLEWIGNIYYSGSTYYNPS HC LRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-20513 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-22216 QVQLQESGPGLVKPSQTLSLTCTVSGGSISDGSYYWSWIRQHPGKGLEWIGNIYYSGSTYYNP HC SLRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGLSTIDEAFDPWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK B7H4-22216 DIQMTQSPSTLSASVGDRVTITCRASKSISSWLAWYQQKPGKAPKLLIYEASSLHSGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQDNSYPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15489 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYSSGSTNYNPSLK HC SRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSGQYAAPDYGMDVWGQGTTVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK B7H4-15489 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQDNSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGECB7H4-20516 QVQLQESGPGLVKPSETLSLTCTVSGGSIISYYWGWIRQPPGKGLEWIGYIYSSGSTSYNPSLKS HC RVTISVDTSKNQFSLKLSSVTAADTAVYYCARGSGLYAAPDYGLDVWGQGTTVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK B7H4-20516 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQDNSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15472 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISGSGGSTYYAD HC SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGAGHYDLVGRYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK B7H4-15472 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG LC SGSGTDFTLTISSLQPEDFATYYCQQLYSLPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15503 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYAD HC SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGFRALNYWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK B7H4-15503 DIQLTQSPSSVSASVGDRVTITCRASQDISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSG LC SGSGTDFTLTISSLQPEDFATYYCQQATSYPPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15495 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTASYAQ HC KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARQQYDGRRYFGLWGRGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK B7H4-15495 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPARFSG LC SGSGTEFTLTISSLQSEDFAVYYCQQVNVWPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15478 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ HC KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGPWFDPWGQGTLVTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK B7H4-15478 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQYNSYPPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-15441 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTSYAD HC SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSLATMLAFDIWGQGTMVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK B7H4-15441 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG LC SGSGTEFTLTISSLQPDDFATYYCQQSKSYPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC B7H4-20496 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSVYYWSWIRQPPGKGLEWIGSILVSGSTYYNPSL HC KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAVSFLDVWGQGTMVIVSSASTKGPSVFPL APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK B7H4-20496 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSG LC SGSGTDFTLTISSLQPEDFATYYCQQSYDPPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC SG-559- TAAIS 01 / PD-L1 CDR-H1 SG-559- GIIPIFGKAHYAQKFQG 01 / PD-L1 CDR-H2 SG-559- KFHFVSGSPFGMDV 01 / PD-L1 CDR-H3 SG-559- RASQSVSSYLA 01 / PD-L1 CDR-L1 SG-559- DASNRAT 01 / PD-L1 CDR-L2 SG-559- QQRSNWPT 01 / PD-L1 CDR-L3 SG-559- QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTAAISWVRQAPGQGLEWMGGIIPIFGKAHYAQ 01 / PD-L1 KFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS VH SG-559- EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA 01 / PD-L1 RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK VL h1F6 CDR- NYGMN H1 h1F6 CDR- WINTYTGEPTYADAFKG H2 h1F6 CDR- DYGDYGMDY H3 h1F6 CDR- RASKSVSTSGYSFMH L1 h1F6 CDR- LASNLES L2 h1F6 CDR- QHSREVPWT L3 h1F6 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPT Y ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS h1F6 VL DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK h1F6 HC QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPT Y ADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK h1F6 LC DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC TROP2 NYGMN CDR-H1 TROP2 WINTYTGEPTYTDDFKG CDR-H2 TROP2 GGFGSSYWYFDV CDR-H3 TROP2 KASQDVSIAVA CDR-L1 TROP2 SASYRYT CDR-L2 TROP2 QQHYITPLT CDR-L3 TROP2 VH QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPT YTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS TROP2 VL DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVP DRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK TROP2 TAGMQ CDR-H1 TROP2 WINTHSGVPKYAEDFKG CDR-H2 TROP2 SGFGSSYWYFDV CDR-H3 TROP2 KASQDVSTAVA CDR-L1 TROP2 SASYRYT CDR-L2 TROP2 QQHYITPLT CDR-L3 TROP2 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPK YAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS TROP2 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFS GSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK MICA CDR- SQNIY H1 MICA CDR- YIEPYNVVPMYNPKFKG H2 MICA CDR- SGSSNFDY H3 MICA CDR- SASSSISSHYLH L1 MICA CDR- RTSNLAS L2 MICA CDR- QQGSSLPLT L3 MICA VH EIQLVQSGAEVKKPGASVKVSCKASGYAFTSQNIYWVRQAPGQGLEWIGYIEPYNVVPMYNP KFKGRATLTVDKSTSTAYLELSSLRSEDTAVYYCARSGSSNFDYWGQGTLVTVSS MICA VL DIQLTQSPSSLSASVGDRVTITCSASSSISSHYLHWYQQKPGKSPKLLIYRTSNLASGVPSRFSG SGSGTDYTLTISSLQPEDFATYYCQQGSSLPLTFGQGTKVEIK MICA CDR- NYAMH H1 MICA CDR- LIWYDGSNKFYGDSVKG H2 MICA CDR- EGSGHY H3 MICA CDR- RASQGISSALA L1 MICA CDR- DASSLES L2MICA CDR- QQFNSYPIT L3 MICA VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGEGLEWVALIWYDGSNKFY GDSVKGRFTISRDNSKNTLYLQMNSLSAEDTAVYYCAREGSGHYWGQGTLVTVSS MICA VL AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKVPKSLIYDASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQFNSYPITFGQGTRLEIK MICA CDR- NYAMS H1 MICA CDR- YISPGGDYIYYADSVKG H2 MICA CDR- DRRHYGSYAMDY H3 MICA CDR- RSSKSLLHSNLNTYLY L1 MICA CDR- RMSNLAS L2 MICA CDR- MQHLEYPFT L3 MICA VH QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWIRQAPGKGLEWVSYISPGGDYIYYAD SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTTDRRHYGSYAMDYWGQGTLVTVSS MICA VL DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNLNTYLYWFLQKPGQSPQILIYRMSNLASGVPD RFSGSGSGTAFTLKISRVEAEDVGVYYCMQHLEYPFTFGPGTKLEIK MICA CDR- TYAFH H1 MICA CDR- GIVPIFGTLKYAQKFQD H2 MICA CDR- AIQLEGRPFDH H3 MICA CDR- RASQGITSYLA L1 MICA CDR- AASALQS L2 MICA CDR- QQVNRGAAIT L3 MICA VH QVQLVQSGAEVKKPGSSVRVSCRASGGSSTTYAFHWVRQAPGQGLEWMGGIVPIFGTLKYA QKFQDRVTLTADKSTGTAYMELNSLRLDDTAVYYCARAIQLEGRPFDHWGQGTQVTVSA MICA VL DIQLTQSPSFLSASVGDRVTITCRASQGITSYLAWYQQKPGKAPKLLIYAASALQSGVPSRFSG RGSGTEFTLTISSLQPEDFATYYCQQVNRGAAITFGHGTRLDIK ITGav / CD51 RYTMH CDR-H1 ITGav / CD51 VISFDGSNKYYVDSVKG CDR-H2 ITGav / CD51 EARGSYAFDI CDR-H3 ITGav / CD51 RASQSVSSYLA CDR-L1 ITGav / CD51 DASNRAT CDR-L2 ITGav / CD51 QQRSNWPPFT CDR-L3 ITGav / CD51 QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYV VH DSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS ITGav / CD51 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG VL SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK ITGav / CD51 SFWMH CDR-H1 ITGav / CD51 YINPRSGYTEYNEIFRD CDR-H2 ITGav / CD51 FLGRGAMDY CDR-H3 ITGav / CD51 RASQDISNYLA CDR-L1 ITGav / CD51 YTSKIHS CDR-L2ITGav / CD51 QQGNTFPYT CDR-L3 ITGav / CD51 QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYN VH EIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS ITGav / CD51 DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSG VL SGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK gpA33 TSSYYWG CDR-H1 gpA33 TIYYNGSTYYSPSLKS CDR-H2 gpA33 QGYDIKINIDV CDR-H3 gpA33 RASQSVSSYLA CDR-L1 gpA33 VASNRAT CDR-L2 gpA33 QQRSNWPLT CDR-L3 gpA33 VH QLQLQESGPGLVKPSETLSLTCTVSGGSISTSSYYWGWIRQPPGKGLEWIGTIYYNGSTYYSPS LKSRVSISVDTSKNQFSLKLSSVTAADTSVYYCARQGYDIKINIDVWGQGTTVTVSS gpA33 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYVASNRATGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK IL1Rap SSWMN CDR-H1 IL1Rap RIYPGDGNTHYAQKFQG CDR-H2 IL1Rap GYLDPMDY CDR-H3 IL1Rap QASQGINNYLN CDR-L1 IL1Rap YTSGLHA CDR-L2 IL1Rap QQYSILPWT CDR-L3 IL1Rap VH QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHY AQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS IL1Rap VL DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFS GSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK EpCAM SYGMH CDR-H1 EpCAM VISYDGSNKYYADSVKG CDR-H2 EpCAM DMGWGSGWRPYYYYGMDV CDR-H3 EpCAM RTSQSISSYLN CDR-L1 EpCAM WASTRES CDR-L2 EpCAM QQSYDIPYT CDR-L3 EpCAM VH EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYA DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQG TTVTVSS EpCAM VL ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK EpCAM NYWMS CDR-H1 EpCAM NIKQDGSEKFYADSVKG CDR-H2 EpCAM VGPSWEQDY CDR-H3 EpCAM TGSSSNIGSYYGVH CDR-L1 EpCAM SDTNRPS CDR-L2EpCAM QSYDKGFGHRV CDR-L3 EpCAM VH EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVANIKQDGSEKFYA DSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGPSWEQDYWGQGTLVTVSA EpCAM VL QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSYYGVHWYQQLPGTAPKLLIYSDTNRPSGVPDRF SGSKSGTSASLAITGLQAEDEADYYCQSYDKGFGHRVFGGGTKLTVL EpCAM SYAIS CDR-H1 EpCAM GIIPIFGTANYAQKFQG CDR-H2 EpCAM GLLWNY CDR-H3 EpCAM RASQSVSSNLA CDR-L1 EpCAM GASTTAS CDR-L2 EpCAM QQYNNWPPAYT CDR-L3 EpCAM VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLLWNYWGQGTLVTVSS EpCAM VL EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLIIYGASTTASGIPARFSAS GSGTDFTLTISSLQSEDFAVYYCQQYNNWPPAYTFGQGTKLEIK EpCAM NYGMN CDR-H1 EpCAM WINTYTGEPTYGEDFKG CDR-H2 EpCAM FGNYVDY CDR-H3 EpCAM RSSKNLLHSNGITYLY CDR-L1 EpCAM QMSNLAS CDR-L2 EpCAM AQNLEIPRT CDR-L3 EpCAM VH QVQLVQSGPEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTY GEDFKGRFAFSLDTSASTAYMELSSLRSEDTAVYFCARFGNYVDYWGQGSLVTVSS EpCAM VL DIVMTQSPLSLPVTPGEPASISCRSSKNLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVP DRFSSSGSGTDFTLKISRVEAEDVGVYYCAQNLEIPRTFGQGTKVEIK EpCAM KYGMN CDR-H1 EpCAM WINTYTEEPTYGDDFKG CDR-H2 EpCAM FGSAVDY CDR-H3 EpCAM RSSKSLLHSNGITYLY CDR-L1 EpCAM QMSNRAS CDR-L2 EpCAM AQNLELPRT CDR-L3 EpCAM VH QIQLVQSGPEVKKPGESVKISCKASGYTFTKYGMNWVKQAPGQGLKWMGWINTYTEEPTYG DDFKGRFTFTLDTSTSTAYLEISSLRSEDTATYFCARFGSAVDYWGQGTLVTVSS EpCAM VL DIVMTQSALSNPVTLGESGSISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNRASGVP DRFSSSGSGTDFTLKISRVEAEDVGVYYCAQNLELPRTFGQGTKLEMKR EpCAM DYSMH CDR-H1 EpCAM WINTETGEPTYADDFKG CDR-H2 EpCAM TAVY CDR-H3 EpCAM RASQEISVSLS CDR-L1 EpCAM ATSTLDS CDR-L2EpCAM LQYASYPWT CDR-L3 EpCAM VH QVKLQESGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWMGWINTETGEPTYA DDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARTAVYWGQGTTVTVSS EpCAM VL DIQMTQSPSSLSASLGERVSLTCRASQEISVSLSWLQQEPDGTIKRLIYATSTLDSGVPKRFSGS RSGSDYSLTISSLESEDFVDYYCLQYASYPWTFGGGTKLEIKR CD352 NYGMN CDR-H1 CD352 WINTYSGEPRYADDFKG CDR-H2 CD352 DYGRWYFDV CDR-H3 CD352 RASSSVSHMH CDR-L1 CD352 ATSNLAS CDR-L2 CD352 QQWSSTPRT CDR-L3 CD352 VH QIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQDLKWMGWINTYSGEPRY ADDFKGRFVFSLDKSVNTAYLQISSLKAEDTAVYYCARDYGRWYFDVWGQGTTVTVSS CD352 VL QIVLSQSPATLSLSPGERATMSCRASSSVSHMHWYQQKPGQAPRPWIYATSNLASGVPARFSG SGSGTDYTLTISSLEPEDFAVYYCQQWSSTPRTFGGGTKVEIKR CS1 / SLAM RYWMS F7 CDR-H1 CS1 / SLAM EINPDSSTINYAPSLKD F7 CDR-H2 CS1 / SLAM PDGNYWYFDV F7 CDR-H3 CS1 / SLAM KASQDVGIAVA F7 CDR-L1 CS1 / SLAM WASTRHT F7 CDR-L2 CS1 / SLAM QQYSSYPYT F7 CDR-L3 CS1 / SLAM EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAP F7 VH SLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS CS1 / SLAM DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFS F7 VL GSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKR CD38 CDR- SFAMS H1 CD38 CDR- AISGSGGGTYYADSVKG H2 CD38 CDR- DKILWFGEPVFDY H3 CD38 CDR- RASQSVSSYLA L1 CD38 CDR- DASNRAT L2 CD38 CDR- QQRSNWPPT L3 CD38 VH EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS CD38 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKR CD25 CDR- SYRMH H1 CD25 CDR- YINPSTGYTEYNQKFKD H2 CD25 CDR- GGGVFDY H3 CD25 CDR- SASSSISYMH L1 CD25 CDR- TTSNLAS L2CD25 CDR- HQRSTYPLT L3 CD25 VH QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYN QKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS CD25 VL DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGS GSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK ADAM9 SYWMH CDR-H1 ADAM9 EIIPINGHTNYNEKFKS CDR-H2 ADAM9 GGYYYYGSRDYFDY CDR-H3 ADAM9 KASQSVDYDGDSYMN CDR-L1 ADAM9 AASDLES CDR-L2 ADAM9 QQSHEDPFT CDR-L3 ADAM9 VH QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEIIPINGHTNYNE KFKSKATLTLDKSSSTAYMQLSSLASEDSAVYYCARGGYYYYGSRDYFDYWGQGTTLTVSS ADAM9 VL DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQIPGQPPKLLIYAASDLESGIPA RFSGSGSGTDFTLNIHPVEEEDAATYYCQQSHEDPFTFGGGTKLEIK ADAM9 SYWMH CDR-H1 ADAM9 EIIPIFGHTNYNEKFKS CDR-H2 ADAM9 GGYYYYPRQGFLDY CDR-H3 ADAM9 KASQSVDYSGDSYMN CDR-L1 ADAM9 AASDLES CDR-L2 ADAM9 QQSHEDPFT CDR-L3 ADAM9 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWVGEIIPIFGHTNYNE KFKSRFTISLDNSKNTLYLQMGSLRAEDTAVYYCARGGYYYYPRQGFLDYWGQGTTVTVSS ADAM9 VL DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWYQQKPGQPPKLLIYAASDLESGIP ARFSGSGSGTDFTLTISSLEPEDFATYYCQQSHEDPFTFGQGTKLEIK CD59 CDR- SYGMN H1 CD59 CDR- YISSSSSTIYYADSVKG H2 CD59 CDR- GPGMDV H3 CD59 CDR- KSSQSVLYSSNNKNYLA L1 CD59 CDR- WASTRES L2 CD59 CDR- QQYYSTPQLT L3 CD59 VH QVQLQQSGGGVVQPGRSLGLSCAASGFTFSSYGMNWVRQAPGKGLEWVSYISSSSSTIYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPGMDVWGQGTTVTVS CD59 VL DIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTPAISSLQAEDVAVYYCQQYYSTPQLTFGGGTKVDIK CD19 TSGMGVG (hBU12) CDR-H1 CD19 HIWWDDDKRYNPALKS (hBU12) CDR-H2 CD19 MELWSYYFDY (hBU12) CDR-H3CD19 SASSSVSYMH (hBU12) CDR-L1 CD19 DTSKLAS (hBU12) CDR-L2 CD19 FQGSVYPFT (hBU12) CDR-L3 CD19 QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYN (hBU12) PALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS VH CD19 EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGS (hBU12) GSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIKR VL CD19 QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKR (hBU12) HC YNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK CD19 EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPAR (hBU12) LC FSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC CD138 NYWIE CDR-H1 CD138 EILPGTGRTIYNEKFKG CDR-H2 CD138 RDYYGNFYYAMDY CDR-H3 CD138 SASQGINNYLN CDR-L1 CD138 YTSTLQS CDR-L2 CD138 QQYSKLPRT CDR-L3 CD138 VH QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIY NEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVS S CD138 VL DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVP SRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK CD166 TYGMGVG CDR-H1 CD166 NIWWSEDKHYSPSLKS CDR-H2 CD166 IDYGNDYAFTY CDR-H3 CD166 RSSKSLLHSNGITYLY CDR-L1 CD166 QMSNLAS CDR-L2 CD166 AQNLELPYT CDR-L3 CD166 VH QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSP SLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS CD166 VL DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK CD56 CDR- SFGMH H1 CD56 CDR- YISSGSFTIYYADSVKG H2 CD56 CDR- MRKGYAMDY H3CD56 CDR- RSSQIIIHSDGNTYLE L1 CD56 CDR- KVSNRFS L2 CD56 CDR- FQGSHVPHT L3 CD56 VH QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS CD56 VL DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK CD74 CDR- NYGVN H1 CD74 CDR- WINPNTGEPTFDDDFKG H2 CD74 CDR- SRGKNEAWFAY H3 CD74 CDR- RSSQSLVHRNGNTYLH L1 CD74 CDR- TVSNRFS L2 CD74 CDR- SQSSHVPPT L3 CD74 VH QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFD DDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS CD74 VL DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK CEACAM5 TYWMS CDR-H1 CEACAM5 EIHPDSSTINYAPSLKD CDR-H2 CEACAM5 LYFGFPWFAY CDR-H3 CEACAM5 KASQDVGTSVA CDR-L1 CEACAM5 WTSTRHT CDR-L2 CEACAM5 QQYSLYRS CDR-L3 CEACAM5 EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPS VH LKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS CEACAM5 DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFS VL GSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK CanAg YYGMN CDR-H1 CanAg WIDTTTGEPTYAQKFQG CDR-H2 CanAg RGPYNWYFDV CDR-H3 CanAg RSSKSLLHSNGNTYLY CDR-L1 CanAg RMSNLVS CDR-L2 CanAg LQHLEYPFT CDR-L3 CanAg VH QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTY AQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS CanAg VL DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVP DRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK DLL-3 NYGMN CDR-H1 DLL-3 WINTYTGEPTYADDFKG CDR-H2 DLL-3 IGDSSPSDY CDR-H3DLL-3 KASQSVSNDVV CDR-L1 DLL-3 YASNRYT CDR-L2 DLL-3 QQDYTSPWT CDR-L3 DLL-3 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPT Y ADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS DLL-3 VL EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPA RFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK DPEP-3 SYWIE CDR-H1 DPEP-3 EILPGSGNTYYNERFKD CDR-H2 DPEP-3 RAAAYYSNPEWFAY CDR-H3 DPEP-3 TASSSVNSFYLH CDR-L1 DPEP-3 STSNLAS CDR-L2 DPEP-3 HQYHRSPYT CDR-L3 DPEP-3 VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYN ERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS DPEP-3 VL EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK EGFR CDR- SYWMQ H1 EGFR CDR- TIYPGDGDTTYTQKFQG H2 EGFR CDR- YDAPGYAMDY H3 EGFR CDR- RASQDINNYLA L1 EGFR CDR- YTSTLHP L2 EGFR CDR- LQYDNLLYT L3 EGFR VH QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYT QKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS EGFR VL DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSG SGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK EGFR CDR- RDFAWN H1 EGFR CDR- YISYNGNTRYQPSLKS H2 EGFR CDR- ASRGFPY H3 EGFR CDR- HSSQDINSNIG L1 EGFR CDR- HGTNLDD L2 EGFR CDR- VQYAQFPWT L3 EGFR VH EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPS LKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS EGFR VL DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSG SGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK EGFR CDR- NYGVH H1 EGFR CDR- VIWSGGNTDYNTPFTS H2 EGFR CDR- ALTYYDYEFAY H3EGFR CDR- RASQSIGTNIH L1 EGFR CDR- YASESIS L2 EGFR CDR- QQNNNWPTT L3 EGFR VH QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTP FTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA EGFR VL DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK FRa CDR- GYFMN H1 FRa CDR- RIHPYDGDTFYNQKFQG H2 FRa CDR- YDGSRAMDY H3 FRa CDR- KASQSVSFAGTSLMH L1 FRa CDR- RASNLEA L2 FRa CDR- QQSREYPYT L3 FRa VH QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFY NQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS FRa VL DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPD RFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK FRa CDR- GYGLS H1 FRa CDR- MISSGGSYTYYADSVKG H2 FRa CDR- HGDDPAWFAY H3 FRa CDR- SVSSSISSNNLH L1 FRa CDR- GTSNLAS L2 FRa CDR- QQWSSYPYMYT L3 FRa VH EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYY ADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS FRa VL DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSG SGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK MUC-1 NYWMN CDR-H1 MUC-1 EIRLKSNNYTTHYAESVKG CDR-H2 MUC-1 HYYFDY CDR-H3 MUC-1 RSSKSLLHSNGITYFF CDR-L1 MUC-1 QMSNLAS CDR-L2 MUC-1 AQNLELPPT CDR-L3 MUC-1 VH EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTT HYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS MUC-1 VL DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPD RFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK Mesothelin SYWIG CDR-H1 Mesothelin IIDPGDSRTRYSPSFQG CDR-H2 Mesothelin GQLYGGTYMDG CDR-H3Mesothelin TGTSSDIGGYNSVS CDR-L1 Mesothelin GVNNRPS CDR-L2 Mesothelin SSYDIESATPV CDR-L3 Mesothelin QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPS VH FQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS Mesothelin DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGV VL SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL ROR-1 AYNIH CDR-H1 ROR-1 SFDPYDGGSSYNQKFKD CDR-H2 ROR-1 GWYYFDY CDR-H3 ROR-1 RASKSISKYLA CDR-L1 ROR-1 SGSTLQS CDR-L2 ROR-1 QQHDESPYT CDR-L3 ROR-1 VH QVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYN QKFKDRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGWYYFDYWGHGTLVTVSS ROR-1 VL DIVMTQTPLSLPVTPGEPASISCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPPRFSGS GYGTDFTLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK B7-H3 SFGMH CDR-H1 B7-H3 YISSDSSAIYYADTVKG CDR-H2 B7-H3 GRENIYYGSRLDY CDR-H3 B7-H3 KASQNVDTNVA CDR-L1 B7-H3 SASYRYS CDR-L2 B7-H3 QQYNNYPFT CDR-L3 B7-H3 VH DVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSDSSAIYY ADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCGRGRENIYYGSRLDYWGQGTTLTVSS B7-H3 VL DIAMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPD RFTGSGSGTDFTLTINNVQSEDLAEYFCQQYNNYPFTFGSGTKLEIK B7-H3 SYGMS CDR-H1 B7-H3 TINSGGSNTYYPDSLKG CDR-H2 B7-H3 HDGGAMDY CDR-H3 B7-H3 RASESIYSYLA CDR-L1 B7-H3 NTKTLPE CDR-L2 B7-H3 QHHYGTPPWT CDR-L3 B7-H3 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATINSGGSNTYY PDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHDGGAMDYWGQGTTVTVSS B7-H3 VL DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPGKAPKLLVYNTKTLPEGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQHHYGTPPWTFGQGTRLEIK B7-H3 SFGMH CDR-H1 B7-H3 YISSGSGTIYYADTVKG CDR-H2 B7-H3 HGYRYEGFDY CDR-H3B7-H3 KASQNVDTNVA CDR-L1 B7-H3 SASYRYS CDR-L2 B7-H3 QQYNNYPFT CDR-L3 B7-H3 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSGTIY YADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHGYRYEGFDYWGQGTTVTVSS B7-H3 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFS GSGSGTDFTLTISSLQPEDFAEYFCQQYNNYPFTFGQGTKLEIK B7-H3 NYVMH CDR-H1 B7-H3 YINPYNDDVKYNEKFKG CDR-H2 B7-H3 WGYYGSPLYYFDY CDR-H3 B7-H3 RASSRLIYMH CDR-L1 B7-H3 ATSNLAS CDR-L2 B7-H3 QQWNSNPPT CDR-L3 B7-H3 VH EVQLQQSGPELVKPGASVKMSCKASGYTFTNYVMHWVKQKPGQGLEWIGYINPYNDDVKY NEKFKGKATQTSDKSSSTAYMELSSLTSEDSAVYYCARWGYYGSPLYYFDYWGQGTTLTVS S B7-H3 VL QIVLSQSPTILSASPGEKVTMTCRASSRLIYMHWYQQKPGSSPKPWIYATSNLASGVPAR FSGSGSGTSYSLTISRVEAEDAATYYCQQWNSNPPTFGTGTKLELK B7-H3 NYVMH CDR-H1 B7-H3 YINPYNDDVKYNEKFKG CDR-H2 B7-H3 WGYYGSPLYYFDY CDR-H3 B7-H3 RASSRLIYMH CDR-L1 B7-H3 ATSNLAS CDR-L2 B7-H3 QQWNSNPPT CDR-L3 B7-H3 VH QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDDVK YNE KFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWGYYGSPLYYFDYWGQGTLVTVSS B7-H3 VL EIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKPGQAPRPLIYATSNLASGIPARFSGSG SGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFGQGTKVEIK B7-H3 SYTIH CDR-H1 B7-H3 YINPNSRNTDYAQKFQG CDR-H2 B7-H3 YSGSTPYWYFDV CDR-H3 B7-H3 RASSSVSYMN CDR-L1 B7-H3 ATSNLAS CDR-L2 B7-H3 QQWSSNPLT CDR-L3 B7-H3 VH EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYTIHWVRQAPGQGLEWMGYINPNSRNTDYA QKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCARYSGSTPYWYFDVWGQGTTVTVSS B7-H3 VL DIQLTQSPSFLSASVGDRVTITCRASSSVSYMNWYQQKPGKSPKPWIYATSNLASGVPSRFSVS VSGTEHTLTISSLQPEDFATYYCQQWSSNPLTFGQGTKLEIK B7-H3 SYWMH CDR-H1 B7-H3 LIHPDSGSTNYNEMFKN CDR-H2B7-H3 GGRLYFDY CDR-H3 B7-H3 RSSQSLVHSNGDTYLR CDR-L1 B7-H3 KVSNRFS CDR-L2 B7-H3 SQSTHVPYT CDR-L3 B7-H3 VH EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYWMHWVRQAPGQGLEWIGLIHPDSGSTNYN EMFKNRATLTVDRSTSTAYVELSSLRSEDTAVYFCAGGGRLYFDYWGQGTTVTVSS B7-H3 VL DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNGDTYLRWYLQKPGQSPQLLIYKVSNRFSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK B7-H3 SYWMH CDR-H1 B7-H3 LIHPESGSTNYNEMFKN CDR-H2 B7-H3 GGRLYFDY CDR-H3 B7-H3 RSSQSLVHSNQDTYLR CDR-L1 B7-H3 KVSNRFS CDR-L2 B7-H3 SQSTHVPYT CDR-L3 B7-H3 VH EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYWMHWVRQAPGQGLEWIGLIHPESGSTNY NEMFKNRATLTVDRSTSTAYMELSSLRSEDTAVYYCAGGGRLYFDYWGQGTTVTVSS B7-H3 VL DIVMTQSPLSLPVTPGEPASISCRSSQSLVHSNQDTYLRWYLQKPGQSPQLLIYKVSNRFSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGGGTKVEIK B7-H3 SGYSWH CDR-H1 B7-H3 YIHSSGSTNYNPSLKS CDR-H2 B7-H3 YDDYFEY CDR-H3 B7-H3 KASQNVGFNVAW CDR-L1 B7-H3 SASYRYS CDR-L2 B7-H3 QQYNWYPFT CDR-L3 B7-H3 VH EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNY NPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS B7-H3 VL DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGV PSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK B7-H3 NYDIN CDR-H1 B7-H3 WIFPGDDSTQYNEKFKG CDR-H2 B7-H3 QTTGTWFAY CDR-H3 B7-H3 RASQSISDYLY CDR-L1 B7-H3 YASQSIS CDR-L2 B7-H3 QNGHSFPLT CDR-L3 B7-H3 VH QVQLVQSGAEVVKPGASVKLSCKTSGYTFTNYDINWVRQRPGQGLEWIGWIFPGDDSTQY NEKFKGKATLTTDTSTSTAYMELSSLRSEDTAVYFCARQTTGTWFAYWGQGTLVTVSS B7-H3 VL EIVMTQSPATLSVSPGERVTLSCRASQSISDYLYWYQQKSHESPRLLIKYASQSISGIPA RFSGSGSGSEFTLTINSVEPEDVGVYYCQNGHSFPLTFGQGTKLELK B7-H3 VH QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIAN YAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGSGSYHMDVWGKGTTVTVSS B7-H3 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIP ARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGQGTRLEIKB7-H3 IYNVH CDR-H1 B7-H3 TIFPGNGDTSYNQKFKD CDR-H2 B7-H3 WDDGNVGFAH CDR-H3 B7-H3 RASENINNYLT CDR-L1 B7-H3 HAKTLAE CDR-L2 B7-H3 QHHYGTPPT CDR-L3 B7-H3 VH QVQLQQPGAELVKPGASVKMSCKASGYTFTIYNVHWIKQTPGQGLEWMGTIFPGNGDTSY NQKFKDKATLTTDKSSKTAYMQLNSLTSEDSAVYYCARWDDGNVGFAHWGQGTLVTVSA B7-H3 VL DIQMTQSPASLSASVGETVTITCRASENINNYLTWFQQKQGKSPQLLVYHAKTLAEGVPS RFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTPPTFGGGTKLEIK B7-H3 VH EVQLVQSGAEVKKPGASVKVSCKASGYTFTIYNVHWVRQAPGQGLEWMGTIFPGNGDTS YNQKFKDKVTMTTDTSTSTAYMELSSLRSEDTAVYYCARWDDGNVGFAHWGQGTLVTVSS B7-H3 VL DIQMTQSPSSLSASVGDRVTITCRASENINNYLTWFQQKQGKSPQLLIYHAKTLAEGVP SRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPPTFGGGTKVEIK B7-H3 VH EVQLVQSGAEVKKPGASVKVSCKASGYTFTIYNVHWIRQAPGQGLEWMGTIFPGNGDTSY NQKFKDRATLTTDKSTKTAYMELRSLRSDDTAVYYCARWDDGNVGFAHWGQGTLVTVSS B7-H3 VL DIQMTQSPSSLSASVGDRVTITCRASENINNYLTWFQQKPGKAPKLLVYHAKTLAEGVPS RFSGSGSGTQFTLTISSLQPEDFATYYCQHHYGTPPTFGQGTKLEIK HER3 H QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYN PSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK HER3 L DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER3 H EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSSA STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRV VSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK HER3 L QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRF SGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVLGQPKAAPSVTLFPPSSEE LQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQW KSHRSYSCRVTHEGSTVEKTVAPAECS HER3 H EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK HER3 L DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC HER3 H QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYN QKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPG HER3 L DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC PTK7 CDR- TSNMGVG H1 PTK7 CDR- HIWWDDDKYYSPSLKS H2 PTK7 CDR- SNYGYAWFAY H3 PTK7 CDR- KASQDIYPYLN L1 PTK7 CDR- RTNRLLD L2 PTK7 CDR- LQYDEFPLT L3 PTK7 VH QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSNMGVGWIRQPPGKALEWLAHIWWDDDKYYSP SLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCVRSNYGYAWFAYWGQGTLVTVSS PTK7 VL DIQMTQSPSSLSASVGDRVTITCKASQDIYPYLNWFQQKPGKAPKTLIYRTNRLLDGVPS RFSGSGSGTDFTFTISSLQPEDIATYYCLQYDEFPLTFGAGTKLEIK PTK7 CDR- DYAVH H1 PTK7 CDR- VISTYNDYTYNNQDFKG H2 PTK7 CDR- GNSYFYALDY H3 PTK7 CDR- RASESVDSYGKSFMH L1 PTK7 CDR- RASNLES L2 PTK7 CDR- QQSNEDPWT L3 PTK7 VH QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTY NNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS PTK7 VL EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLES GIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK PTK7 CDR- RYWMS H1 PTK7 CDR- DLNPDSSAINYVDSVKG H2 PTK7 CDR- ITTLVPYTMDF H3 PTK7 CDR- ITNTDIDDDMN L1 PTK7 CDR- EGNGLRP L2 PTK7 CDR- LQSDNLPLT L3 PTK7 VH EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGDLNPDSSAINY VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTLITTLVPYTMDFWGQGTSVTVSS PTK7 VL ETTLTQSPAFMSATPGDKVNISCITNTDIDDDMNWYQQKPGEAAILLISEGNGLRPGIPPRFSGS GYGTDFTLTINNIESEDAAYYFCLQSDNLPLTFGSGTKLEIK hLIV22 / LIV DYYMH 1 CDR-H1 hLIV22 / LIV WIDPENGDTEYGPKFQG 1 CDR-H2 hLIV22 / LIV HNAHYGTWFAY 1 CDR-H3 hLIV22 / LIV RSSQSLLHSSGNTYLE 1 CDR-L1 hLIV22 / LIV KISTRFS 1 CDR-L2hLIV22 / LIV FQGSHVPYT 1 CDR-L3 hLIV22 / LIV QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEY 1 VH GPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS hLIV22 / LIV DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPD 1 VL RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK hLIV22 / LIV QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEY 1 HC GPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG hLIV22 / LIV DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPD 1 LC RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADY EKHKVYACEVTHQGLSSPVTKSFNRGEC h15H3 / avb6 GYFMN CDR-H1 h15H3 / avb6 LINPYNGDSFYNQKFKG CDR-H2 h15H3 / avb6 GLRRDFDY CDR-H3 h15H3 / avb6 KSSQSLLDSDGKTYLN CDR-L1 h15H3 / avb6 LVSELDS CDR-L2 h15H3 / avb6 WQGTHFPRT CDR-L3 h15H3 / avb6 QVQLVQSGAEVKKPGASVKVSCKASGYSFSGYFMNWVRQAPGQGLEWMGLINPYNGDSFY VH NQKFKGRVTMTRQTSTSTVYMELSSLRSEDTAVYYCVRGLRRDFDYWGQGTLVTVSS h15H3 / avb6 DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTYLNWLFQRPGQSPRRLIYLVSELD VL SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGGGTKLEIK CD48 CDR- DFGMN H1 CD48 CDR- WINTFTGEPSYGNVFKG H2 CD48 CDR- RHGNGNVFDS H3 CD48 CDR- RASQSIGSNIH L1 CD48 CDR- YTSESIS L2 CD48 CDR- QQSNSWPLT L3 CD48 VH QVQLVQSGSELKKPGASVKVSCKASGYTFTDFGMNWVRQAPGQGLEWMGWINTFTGEPSY GNVFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARRHGNGNVFDSWGQGTLVTVSS CD48 VL EIVLTQSPDFQSVTPKEKVTITCRASQSIGSNIHWYQQKPDQSPKLLIKYTSESISGVPSRFSGSG SGTDFTLTINSLEAEDAATYYCQQSNSWPLTFGGGTKVEIKR IGF-1R SYAIS CDR-H1 IGF-1R GIIPIFGTANYAQKFQG CDR-H2 IGF-1R APLRFLEWSTQDHYYYYYMDV CDR-H3 IGF-1R QGDSLRSYYAT CDR-L1 IGF-1R GENKRPS CDR-L2 IGF-1R KSRDGSGQHLV CDR-L3 IGF-1R VH EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY AQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWG KGTTVTVSSIGF-1R VL SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDR FSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL Claudin-18.2 SYWIN CDR-H1 Claudin-18.2 NIYPSDSYTNYNQKFKD CDR-H2 Claudin-18.2 SWRGNSFDY CDR-H3 Claudin-18.2 KSSQSLLNSGNQKNYLT CDR-L1 Claudin-18.2 WASTRES CDR-L2 Claudin-18.2 QNDYSYPFT CDR-L3 Claudin-18.2 QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTN VH YNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS Claudin-18.2 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR VL ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK Claudin-18.2 NYGMN CDR-H1 Claudin-18.2 WINTNTGEPTYAEEFKG CDR-H2 Claudin-18.2 LGFGNAMDY CDR-H3 Claudin-18.2 KSSQSLLNSGNQKNYLT CDR-L1 Claudin-18.2 WASTRES CDR-L2 Claudin-18.2 QNDYSYPLT CDR-L3 Claudin-18.2 QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTNTGEPTY VH AEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARLGFGNAMDYWGQGTSVTVSS Claudin-18.2 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR VL ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLELK Nectin-4 SYNMN CDR-H1 Nectin-4 YISSSSSTIYYADSVKG CDR-H2 Nectin-4 AYYYGMDV CDR-H3 Nectin-4 RASQGISGWLA CDR-L1 Nectin-4 AASTLQS CDR-L2 Nectin-4 QQANSFPPT CDR-L3 Nectin-4 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYY ADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS Nectin-4 VL DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK SLTRK6 SYGMH CDR-H1 SLTRK6 VIWYDGSNQYYADSVKG CDR-H2 SLTRK6 GLTSGRYGMDV CDR-H3 SLTRK6 RSSQSLLLSHGFNYLD CDR-L1 SLTRK6 LGSSRAS CDR-L2 SLTRK6 MQPLQIPWT CDR-L3 SLTRK6 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYY VH ADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSSSLTRK6 VL DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPD RFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK CD142 (TF) NYAMS CDR-H1 CD142 (TF) SISGSGDYTYYTDSVKG CDR-H2 CD142 (TF) SPWGYYLDS CDR-H3 CD142 (TF) RASQGISSRLA CDR-L1 CD142 (TF) AASSLQS CDR-L2 CD142 (TF) QQYNSYPYT CDR-L3 CD142 (TF) EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTY VH YTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS CD142 (TF) DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPS VL RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK h2G12 / STn DHAIH CDR-H1 h2G12 / STn YFSPGNDDIKYNEKFRG CDR-H2 h2G12 / STn SLSTPY CDR-H3 h2G12 / STn KSSQSLLNRGNHKNYLT CDR-L1 h2G12 / STn WASTRES CDR-L2 h2G12 / STn QNDYTYPYT CDR-L3 h2G12 / STn EVQLVQSGAEVKKPGASVKVSCKASGYTFTDHAIHWVRQAPGQGLEWMGYFSPGNDDIKY VH NEKFRGRVTMTADKSSSTAYMELRSLRSDDTAVYFCKRSLSTPYWGQGTLVTVSS h2G12 / STn DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNHKNYLTWYQQKPGQPPKLLIYWAST VL RESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPYTFGQGTKVEIK CD20 CDR- SYNMH H1 CD20 CDR- AIYPGNGDTSYNQKFKG H2 CD20 CDR- STYYGGDWYFNV H3 CD20 CDR- RASSSVSYIH L1 CD20 CDR- ATSNLAS L2 CD20 CDR- QQWTSNPPT L3 CD20 VH QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSY NQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS A CD20 VL QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVR FSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK HER2 CDR- DTYIH H1 HER2 CDR- RIYPTNGYTRYADSVKG H2 HER2 CDR- WGGDGFYAMDY H3 HER2 CDR- RASQDVNTAVA L1 HER2 CDR- SASFLYS L2 HER2 CDR- QQHYTTPPT L3 HER2 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSHER2 VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK CD79b SYWIE CDR-H1 CD79b EILPGGGDTNYNEIFKG CDR-H2 CD79b RVPIRLDY CDR-H3 CD79b KASQSVDYEGDSFLN CDR-L1 CD79b AASNLES CDR-L2 CD79b QQSNEDPLT CDR-L3 CD79b VH EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEI FKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS CD79b VL DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLES GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK NaPi2B DFAMS CDR-H1 NaPi2B TIGRVAFHTYYPDSMKG CDR-H2 NaPi2B HRGFDVGHFDF CDR-H3 NaPi2B RSSETLVHSSGNTYLE CDR-L1 NaPi2B RVSNRFS CDR-L2 NaPi2B FQGSFNPLT CDR-L3 NaPi2B VH EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYY PDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS NaPi2B VL DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRF SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK Muc16 NDYAWN CDR-H1 Muc16 YISYSGYTTYNPSLKS CDR-H2 Muc16 WTSGLDY CDR-H3 Muc16 KASDLIHNWLA CDR-L1 Muc16 GATSLET CDR-L2 Muc16 QQYWTTPFT CDR-L3 Muc16 VH EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTY NPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS Muc16 VL DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK STEAP1 SDYAWN CDR-H1 STEAP1 YISNSGSTSYNPSLKS CDR-H2 STEAP1 ERNYDYDDYYYAMDY CDR-H3 STEAP1 KSSQSLLYRSNQKNYLA CDR-L1 STEAP1 WASTRES CDR-L2 STEAP1 QQYYNYPRT CDR-L3 STEAP1 VH EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNP SLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVS SSTEAP1 VL DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK BCMA NYWMH CDR-H1 BCMA ATYRGHSDTYYNQKFKG CDR-H2 BCMA GAIYDGYDVLDN CDR-H3 BCMA SASQDISNYLN CDR-L1 BCMA YTSNLHS CDR-L2 BCMA QQYRKLPWT CDR-L3 BCMA VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTY YNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVS S BCMA VL DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK c-Met CDR- AYTMH H1 c-Met CDR- WIKPNNGLANYAQKFQG H2 c-Met CDR- SEITTEFDY H3 c-Met CDR- KSSESVDSYANSFLH L1 c-Met CDR- RASTRES L2 c-Met CDR- QQSKEDPLT L3 c-Met VH QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLAN YAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS c-Met VL DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRE SGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK EGFR CDR- SDFAWN H1 EGFR CDR- YISYSGNTRYQPSLKS H2 EGFR CDR- AGRGFPY H3 EGFR CDR- HSSQDINSNIG L1 EGFR CDR- HGTNLDD L2 EGFR CDR- VQYAQFPWT L3 EGFR VH QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRY QPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS EGFR VL DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPS RFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK SLAMF7 DYYMA CDR-H1 SLAMF7 SINYDGSSTYYVDSVKG CDR-H2 SLAMF7 DRGYYFDY CDR-H3 SLAMF7 RSSQSLVHSNGNTYLH CDR-L1 SLAMF7 KVSNRFS CDR-L2 SLAMF7 SQSTHVPPFT CDR-L3 SLAMF7 EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTY VH YVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSSSLAMF7 DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRF VL SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK C4.4a CDR- NAWMS H1 C4.4a CDR- YISSSGSTIYYADSVKG H2 C4.4a CDR- EGLWAFDY H3 C4.4a CDR- TGSSSNIGAGYVVH L1 C4.4a CDR- DNNKRPS L2 C4.4a CDR- AAWDDRLNGPV L3 C4.4a VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS C4.4a VL ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGV PDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL GCC CDR- GYYWS H1 GCC CDR- EINHRGNTNDNPSLKS H2 GCC CDR- ERGYTYGNFDH H3 GCC CDR- RASQSVSRNLA L1 GCC CDR- GASTRAT L2 GCC CDR- QQYKTWPRT L3 GCC VH QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDN PSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS GCC VL EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIP ARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK Axl CDR- SYAMN H1 Axl CDR- TTSGSGASTYYADSVKG H2 Axl CDR- IWIAFDI H3 Axl CDR-L1 RASQSVSSSYLA Axl CDR-L2 GASSRAT Axl CDR-L3 QQYGSSPYT Axl VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS Axl VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK CR011 / gpN SFNYYWS MB CDR- H1 CR011 / gpN YIYYSGSTYSNPSLKS MB CDR- H2 CR011 / gpN GYNWNYFDY MB CDR- H3 CR011 / gpN RASQSVDNNLV MB CDR- L1 CR011 / gpN GASTRAT MB CDR- L2 CR011 / gpN QQYNNWPPWT MB CDR- L3CR011 / gpN QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTY MB VH SNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS CR011 / gpN EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPA MB VL RFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK CR011 / gpN QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPS MB HC LKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK CR011 / gpN EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFS MB LC GSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK HKVYACEVTHQGLSSPVTKSFNRGEC Prolactin TYWMH receptor CDR-H1 Prolactin EIDPSDSYSNYNQKFKD receptor CDR-H2 Prolactin NGGLGPAWFSY receptor CDR-H3 Prolactin KASQYVGTAVA receptor CDR-L1 Prolactin SASNRYT receptor CDR-L2 Prolactin QQYSSYPWT receptor CDR-L3 Prolactin EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNY receptor VH NQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS Prolactin DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPS receptor VL RFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK FGFR2 SYAMS CDR-H1 FGFR2 AISGSGTSTYYADSVKG CDR-H2 FGFR2 VRYNWNHGDWFDP CDR-H3 FGFR2 SGSSSNIGNNYVS CDR-L1 FGFR2 ENYNRPA CDR-L2 FGFR2 SSWDDSLNYWV CDR-L3 FGFR2 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS FGFR2 VL QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVP DRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL CDCP1 SYGMS CDR-H1 CDCP1 TISSGGSYKYYVDSVKG CDR-H2 CDCP1 HPDYDGVWFAY CDR-H3 CDCP1 SVSSSVFYVH CDR-L1 CDCP1 DTSKLAS CDR-L2 CDCP1 QQWNSNPPT CDR-L3CDCP1 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFNSYGMSWVRQAPGKGLEWVATISSGGSYKYY VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHPDYDGVWFAYWGQGTLVTVSS CDCP1 VL DIQMTQSPSSLSASVGDRVTITCSVSSSVFYVHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGS GSGTDFTFTISSLQPEDIATYYCQQWNSNPPTFGGGTKVEIK CDCP1 SYGMS CDR-H1 CDCP1 TISSGGSYTYYPDSVKG CDR-H2 CDCP1 HPDYDGVWFAY CDR-H3 CDCP1 SVSSSVFYVH CDR-L1 CDCP1 DTSKLAS CDR-L2 CDCP1 QQWNSNPPT CDR-L3 CDCP1 VH EVQLVESGGDLVKPGGSLKLSCAASGFTFNSYGMSWVRQTPDKRLEWVATISSGGSYTYY PDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHPDYDGVWFAYWGQGTLVTVSA CDCP1 VL QIVLTQSPAIMSASPGEKVTMTCSVSSSVFYVHWYQQKSGTSPKRWIYDTSKLASGVPARF SGSGSGTSYSLTISSMEAEDAATYYCQQWNSNPPTFGGGTKLEIK CDCP1 SYYMH CDR-H1 CDCP1 IINPSGGSTSYAQKFQG CDR-H2 CDCP1 DGVLRYFDWLLDYYYYMDV CDR-H3 CDCP1 RASQSVGSYLA CDR-L1 CDCP1 DASNRAT CDR-L2 CDCP1 QQRANVFT CDR-L3 CDCP1 VH EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDGVLRYFDWLLDYYYYMDVWG KG TTVTVSS CDCP1 VL EIVLTQSPATLSLSPGERATLSCRASQSVGSYLAWYQQRPGQAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRANVFTFGQGTKVEIK CDCP1 SYYMH CDR-H1 CDCP1 IINPSGGSTSYAQKFQG CDR-H2 CDCP1 DAELRHFDHLLDYHYYMDV CDR-H3 CDCP1 RASQSVGSYLA CDR-L1 CDCP1 DASNRAT CDR-L2 CDCP1 QQRAQEFT CDR-L3 CDCP1 VH EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYA QKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDAELRHFDHLLDYHYYMDVWGQG TTVTVSS CDCP1 VL EIVMTQSPATLSLSPGERATLSCRASQSVGSYLAWYQQKPGQAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSLQPEDFAVYYCQQRAQEFTFGQGTKVEIK ASCT2 VH QVQLVQSGSELKKPGAPVKVSCKASGYTFSTFGMSWVRQAPGQGLKWMGWIHTYAGVPIY GDDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARRSDNYRYFFDYWGQGTTVTVSS ASCT2 VL DIQMTQSPSSLSASLGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSG SGSGTDYTLTISSLQPEDFATYFCQQGHTLPPTFGQGTKLEIK ASCT2 VH QIQLVQSGPELKKPGAPVKISCKASGYTFTTFGMSWVKQAPGQGLKWMGWIHTYAGVPIYG DDFKGRFVFSLDTSVSTAYLQISSVKAEDTATYFCARRSDNYRYFFDYWGQGTTLTVSS ASCT2 VL DIQMTQSPSSLSASLGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLHSGVPS RFSGSGSGTDYTLTISSLQPEDFATYFCQQGHTLPPTFGQGTKLEIK ASCT2 NYYMA CDR-H1986 ASCT2 SITKGGGNTYYRDSVKG CDR-H2 987 ASCT2 QVTIAAVSTSYFDS CDR-H3 988 ASCT2 KTNQKVDYYGNSYVY CDR-L1 989 ASCT2 LASNLAS CDR-L2 990 ASCT2 QQSRNLPYT CDR-L3 991 ASCT2 VH EVQLVESGGGLVQSGRSIRLSCAASGFSFSNYYMAWVRQAPSKGLEWVASITKGGGNTYYR DSVKGRFTFSRDNAKSTLYLQMDSLRSEDTATYYCARQVTIAAVSTSYFDSWGQGVMVTVSS 992 ASCT2 VL DIVLTQSPALAVSLGQRATISCKTNQKVDYYGNSYVYWYQQKPGQQPKLLIYLASNLASGIPA RFSGRGSGTDFTLTIDPVEADDTATYYCQQSRNLPYTFGAGTKLELK 993 CD123 DYYMK CDR-H1 994 CD123 DIIPSNGATFYNQKFKG CDR-H2 995 CD123 SHLLRASWFAY CDR-H3 996 CD123 KSSQSLLNSGNQKNYLT CDR-L1 997 CD123 WASTRES CDR-L2 998 CD123 QNDYSYPYT CDR-L3 999 CD123 VH QVQLVQSGAEVKKPGASVKMSCKASGYTFTDYYMKWVKQAPGQGLEWIGDIIPSNGATFYN QKFKGKATLTVDRSISTAYMHLNRLRSDDTAVYYCTRSHLLRASWFAYWGQGTLVTVSS 1000 CD123 VL DFVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYLQKPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK 1001 GPC3 CDR- DYEMH H1 1002 GPC3 CDR- GIDPETGGTAYNQKFKG H2 1003 GPC3 CDR- YYSFAY H3 1004 GPC3 CDR- RSSQSIVHSNANTYLQ L1 1005 GPC3 CDR- KVSNRFS L2 1006 GPC3 CDR- FQVSHVPYT L3 1007 GPC3 VH EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYEMHWVQQAPGKGLEWMGGIDPETGGTAY NQKFKGRVTLTADKSTDTAYMELSSLRSEDTAVYYCGRYYSFAYWGQGTLVTVSS 1008 GPC3 VL DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNANTYLQWFQQRPGQSPRLLIYKVSNRFSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCFQVSHVPYTFGQGTKLEIK 1009 TIGIT CDR- SYAIS H1 1010 TIGIT CDR- SIIPIFGTANYAQKFQG H2 1011 TIGIT CDR- GPSEVGAILGYVWFDP H3 1012 TIGIT CDR- RSSQSLLHSNGYNYLD L1 1013 TIGIT CDR- LGSNRAS L2 1014 TIGIT CDR- MQARRIPIT L3 1015 TIGIT VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGSIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPSEVGAILGYVWFDPWGQGTLVTVS S 1016 TIGIT VL DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARRIPITFGGGTKVEIK 1017 CD33 CDR- NYDIN H11018 CD33 CDR- WIYPGDGSTKYNEKFKA H2 1019 CD33 CDR- GYEDAMDY H3 1020 CD33 CDR- KASQDINSYLS L1 1021 CD33 CDR- RANRLVD L2 1022 CD33 CDR- LQYDEFPLT L3 1023 CD33 VH QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW IYPGDGSTKY NEKFKAKATL TADTSTSTAY MELRSLRSDD TAVYYCASGY EDAMDYWGQG TTVTVSS 1024 CD33 VL DIQMTQSPS SLSASVGDRVT INCKASQDINSYLSWFQQKPGKAPKTL IYRANRLVDGVPS RFSGSGSGQDYTLT ISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK 1025 BCMA DYYIH CDR-H1 1026 BCMA YINPNSGYTNYAQKFQG CDR-H2 1027 BCMA YMWERVTGFFDF CDR-H3 1028 BCMA LASEDISDDLA CDR-L1 1029 BCMA TTSSLQS CDR-L2 1030 BCMA QQTYKFPPT CDR-L3 1031 BCMA VH QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYIHWVRQAPGQGLEWIGYINPNSGYTNYA QKFQGRATMTADKSINTAYVELSRLRSDDTAVYFCTRYMWERVTGFFDFWGQGTMVTVSS 1032 BCMA VL DIQMTQSPSSVSASVGDRVTITCLASEDISDDLAWYQQKPGKAPKVLVYTTSSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYFCQQTYKFPPTFGGGTKVEIK 1033 <Q13433; MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL protein FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSEH EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF 1034 hLIV22 KGAHRPEH epitope 1035 CD24 CDR- TYAFH H1 1036 CD24 CDR- GIVPIFGTLKYAQKFQD H2 1037 CD24 CDR- AIQLEGRPFDH H3 1038 CD24 CDR- RASQGITSYLA L1 1039 CD24 CDR- AASALQS L2 1040 CD24 CDR- QQVNRGAAIT L3 1041 CD24 VH QVQLVQSGAEVKKPGSSVRVSCRASGGSSTTYAFHWVRQAPGQGLEWMGGIVPIFGTLKYA QKFQDRVTLTADKSTGTAYMELNSLRLDDTAVYYCARAIQLEGRPFDHWGQGTQVTVSA 1042 CD24 VL DIQLTQSPSFLSASVGDRVTITCRASQGITSYLAWYQQKPGKAPKLLIYAASALQSGVPS RFSGRGSGTEFTLTISSLQPEDFATYYCQQVNRGAAITFGHGTRLDIK 1043 RL peptide GGGG1044 RL peptide GVKG 1045 RL peptide VKGG 1046 RL peptide GGFG 1047 RL peptide GGFGG 1048 RC48 CDR- DYYIH H1 1049 RC48 CDR- RVNPDHGDSYYNQKFKD H2 1050 RC48 CDR- NYLFDH H3 1051 RC48 CDR- KASQDVGTAVA L1 1052 RC48 CDR- WASIRHT L2 1053 RC48 CDR- HQFATYT L3 1054 RC48 VH EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYY NQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS 1055 RC48 VL DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK 1056 RC48 HC EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYY NQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK 1057 RC48 HC v2 EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYY NQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPG 1058 RC48 LC DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC 1101 cAC10 DYYIT CDR-H1 1102 cAC10 WIYPGSGNTKYNEKFKG CDR-H2 1103 cAC10 YGNYWFAY CDR-H3 1104 cAC10 KASQSVDFDGDSYMN CDR-L1 1105 cAC10 AASNLES CDR-L2 1106 cAC10 QQSNEDPWT CDR-L3 1107 cAC10 VH QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNE KFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA 1108 cAC10 VL DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIP ARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK 1109 cAC10 HC QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNE KFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK1110 cAC10 HC QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNE v2 KFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG 1111 cAC10 LC DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLES GIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIKR TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1112 h1C1 CDR- HYMMA H1 1113 h1C1 CDR- RIGPSGGPTHYADSVKG H2 1114 h1C1 CDR- YDSGYDYVAVAGPAEYFQH H3 1115 h1C1 CDR- RASQSISTWLA L1 1116 h1C1 CDR- KASNLHT L2 1117 h1C1 CDR- QQYNSYSRT L3 1118 h1C1 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYMMAWVRQAPGKGLEWVSRIGPSGGPTHYA DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGYDSGYDYVAVAGPAEYFQHWGQG TLVTVSS 1119 h1C1 VL DIQMTQSPSSLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASNLHTGVPSRFSG SGSGTEFSLTISGLQPDDFATYYCQQYNSYSRTFGQGTKVEIK 1120 h1C1 HC EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYMMAWVRQAPGKGLEWVSRIGPSGGPTHYA DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGYDSGYDYVAVAGPAEYFQHWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1121 h1C1 HC v2 EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYMMAWVRQAPGKGLEWVSRIGPSGGPTHYA DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGYDSGYDYVAVAGPAEYFQHWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG 1122 h1C1 LC DIQMTQSPSSLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASNLHTGVPSRFSG SGSGTEFSLTISGLQPDDFATYYCQQYNSYSRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1123 h1C1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYMMAWVRQAPGKGLEWVSRIGPSGGPTHYA mIgG2a HC DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGYDSGYDYVAVAGPAEYFQHWGQG TLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAV LQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGP SVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRV VSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPEDIYVE...

Claims

CLAIMS What is claimed is:

1. A method of reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC), comprising administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function, and wherein the administration of the ADC results in decreased likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in the individual, as compared to likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

2. The method of claim 1, wherein the administration results in decreased likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in the individual, as compared to likelihood and / or severity of neurotoxicity, peripheral motor neuropathy, peripheral sensorial neuropathy, paresthesia, and / or muscle weakness in an individual administered an ADC comprising a human Fc region with wild-type effector function.

3. The method of claim 1 or claim 2, wherein the administration results in decreased likelihood and / or severity of neutropenia and / or neutrophil count decrease in the individual, as compared to likelihood and / or severity of neutropenia and / or neutrophil count decrease in an individual administered an ADC comprising a human Fc region with wild-type effector function.

4. The method of any one of claims 1-3, wherein the neutropenia does not comprise febrile neutropenia.

5. The method of any one of claims 1-4, wherein the peripheral neuropathy, anemia, and / or neutropenia comprises grade 3 or grade 4 peripheral neuropathy, anemia, and / or neutropenia.

6. The method of any one of claims 1-5, wherein the administration results in a reduction in the likelihood of peripheral neuropathy in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%, as compared to the likelihood of peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function.

7. The method of claim 6, wherein the administration results in a reduction in the likelihood of grade 3 or grade 4 peripheral neuropathy in the individual by at least 50%, at least 55%, at least 60%,at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%, as compared to the likelihood of grade 3 or grade 4 peripheral neuropathy in an individual administered an ADC comprising a human Fc region with wild-type effector function.

8. The method of claim 7, wherein the administration does not result in grade 3 or grade 4 peripheral neuropathy in the individual.

9. The method of any one of claims 1-8, wherein the administration results in a reduction in the likelihood of anemia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, as compared to the likelihood of anemia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

10. The method of claim 9, wherein the administration results in a reduction in the likelihood of grade 3 or grade 4 anemia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as compared to the likelihood of grade 3 or grade 4 anemia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

11. The method of any one of claims 1-10, wherein the administration results in a reduction in the likelihood of neutropenia in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%, as compared to the likelihood of neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

12. The method of claim 11, wherein the administration results in a reduction in the likelihood of grade 3 or grade 4 neutropenia in the individual by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as compared to the likelihood of grade 3 or grade 4 neutropenia in an individual administered an ADC comprising a human Fc region with wild-type effector function.

13. A method of increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual, comprising administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function, and wherein the ADC is administered to the individual at an increased amount and / or at a higher frequency, as compared to amount and / or frequency of dosing in an individual administered an ADC comprising a human Fc region with wild-type effector function.

14. The method of claim 13, wherein the ADC is administered to the individual at an increased amount, as compared to an amount of an ADC comprising a human Fc region with wild-type effector function administered to the individual.

15. The method of claim 13 or claim 14, wherein the ADC is administered to the individual at an increased frequency, as compared to a frequency of administration of an ADC comprising a human Fc region with wild-type effector function to the individual.

16. The method of any one of claims 13-15, wherein the ADC is administered to the individual at an increased amount as compared to a reference amount, and wherein the administration of the ADC at the increased amount does not increase likelihood and / or severity of one or more adverse events in the individual, as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference amount.

17. The method of any one of claims 13-16, wherein the ADC is administered to the individual at an increased frequency as compared to a reference frequency, and wherein the administration of the ADC at the increased frequency does not increase likelihood and / or severity of one or more adverse events in the individual, as compared to likelihood and / or severity of the one or more adverse events in the individual when administered an ADC comprising a human Fc region with wild-type effector function at the reference frequency.

18. The method of claim 16 or claim 17, wherein the one or more adverse events comprise peripheral neuropathy, anemia, and / or neutropenia.

19. The method of claim 18, wherein the one or more adverse events comprise grade 3 or grade 4 peripheral neuropathy, anemia, and / or neutropenia.

20. The method of any one of claims 1-19, wherein the human Fc region has reduced or eliminated binding to one or more human Fc receptor(s), as compared to binding of a human Fc region with wild-type effector function to the one or more human Fc receptor(s).

21. The method of claim 20, wherein the one or more human Fc receptor(s) are human FcγRI, FcγRII, and / or FcγRIII Fc receptors.

22. The method of any one of claims 1-21, wherein the human Fc region has reduced or eliminated binding to complement C1q, as compared to binding of a human Fc region with wild-type effector function to complement C1q.

23. The method of any one of claims 1-22, wherein the human Fc region comprises one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human Fc region.

24. The method of claim 23, wherein the human Fc region is a human IgG1 Fc region comprising one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human IgG1 Fc region.

25. The method of claim 24, wherein the human Fc region is a human IgG1 Fc region comprising an amino acid substitution at one or more of position(s) L234, L235, G236, and / or G237, numbering according to EU index 26. The method of claim 25, wherein the human Fc region is a human IgG1 Fc region comprising amino acid substitution(s) at position(s) L234 and / or L235, numbering according to EU index.

27. The method of claim 26, wherein the human Fc region is a human IgG1 Fc region comprising L234A and L235A substitutions, numbering according to EU index.

28. The method of claim 23, wherein the human Fc region is a human IgG2 Fc region comprising one or more mutations that reduce or eliminate effector function, as compared to effector function of a wild-type human IgG2 Fc region.

29. The method of any one of claims 1-22, wherein the human Fc region is a human IgG4 Fc region.

30. The method of any one of claims 1-29, wherein the individual has or has been diagnosed with cancer.

31. The method of any one of claims 1-30, wherein the individual is being treated for cancer.

32. The method of claim 30 or claim 31, wherein the cancer is melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, or cervical cancer.

33. The method of any one of claims 1-32, wherein the antibody binds to human PD-L1.

34. The method of claim 33, wherein the antibody comprises heavy chain CDR sequences of SEQ ID NOs: 13-15 and light chain CDR sequences of SEQ ID NOs: 16-18.

35. The method of claim 33, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO: 11 and a light chain variable region sequence of SEQ ID NO:

12.

36. The method of claim 33, wherein the antibody comprises a light chain of SEQ ID NO: 9 and a heavy chain of SEQ ID NO: 10.

37. The method of any one of claims 1-32, wherein the antibody binds to human B7-H4, CD19, CD30, CD33, CD70, CD228, ITGB6 (integrin beta 6), Nectin-4, TF (tissue factor), Her2, STn, ALPP, or LIV-1.

38. The method of any one of claims 1-37, wherein the drug moiety is a cytotoxic agent, growth inhibitory agent, or chemotherapy.

39. The method of claim 38, wherein the cytotoxic agent is a tubulin disrupting agent or tubulin / microtubule inhibitor.

40. The method of claim 38 or claim 39, wherein the cytotoxic agent is an auristatin, anthracycline, camptothecin, taxane or taxane analog, vinca alkyloid, baccatin derivative, nocodazole, colchicine, colcimid, estramustine, cryptophysin, cemadotin, maytansinoid, combretastatin, discodermoide, eleuthrobin, or tubulysin.

41. The method of any one of claims 1-40, wherein the drug moiety is monomethyl auristatin E (MMAE).

42. The method of claim 41, wherein the antibody is conjugated to MMAE via a linker forming an antibody-drug conjugate having the structure:wherein Ab represents the antibody and p ranges from 2 to 10.

43. The method of claim 42, wherein p is 4.

44. The method of claim 42, wherein p is 8.

45. The method of any one of claims 1-40, wherein the cytotoxic agent is camptothecin.

46. The method of claim 45, wherein the antibody is conjugated to camptothecin via a linker forming an antibody-drug conjugate having the structure:wherein Ab represents the antibody and p ranges from 2 to 10.

47. The method of claim 46, wherein p is 4.

48. The method of claim 46, wherein p is 8.

49. The method of any one of claims 1-48, wherein the linker is an enzyme-cleavable linker.

50. The method of any one of claims 1-49, wherein the linker is a valine-citrulline (Val-Cit) linker.

Images